Document:

Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

Ver. EQ. 10/15/10

 

MASSACHUSETTS INSTITUTE OF TECHNOLOGY

 

AND

 

ENUMERAL BIOMEDICAL CORP

 

EXCLUSIVE PATENT LICENSE AGREEMENT

 

    	 

    	 

    

 

TABLE OF CONTENTS

 

	RECITALS	1
	1.  Definitions.	3
	2.  Grant of Rights.	13
	3.  COMPANY Diligence Obligations.	17
	4.  Royalties and Payment Terms.	20
	5.  Reports and Records.	31
	6.  Patent Prosecution.	35
	7.  Infringement.	36
	8.  Indemnification and Insurance	39
	9.  No Representations or Warranties	42
	10.  Assignment.	42
	11.  General Compliance with Laws	43
	12.  Termination	44
	13.  Dispute Resolution.	47
	14.  Miscellaneous.	48
	APPENDIX A	52
	APPENDIX B	53
	APPENDIX C	54
	APPENDIX D	55
	EXHIBIT A-1	1
	EXHIBIT A-2	3
	EXHIBIT B-1	5
	EXHIBIT B-2	6

 

    	ii

    	 

    

 

Ver. EQ. 10/15/10

MASSACHUSETTS INSTITUTE OF TECHNOLOGY

EXCLUSIVE PATENT LICENSE AGREEMENT

 

This Agreement, effective as of the date
set forth above the signatures of the parties below (the "EFFECTIVE DATE"), is between the Massachusetts Institute of
Technology ("M.I.T."), a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA
02139-4307 and Enumeral Biomedical Corp., Inc. ("COMPANY"), a Delaware corporation, with a principal place of business
at 1450 Broadway, 24th Floor, New York, NY 10018.

 

RECITALS

 

WHEREAS, M.I.T. is the owner or joint owner
of certain PATENT RIGHTS (as later defined herein) relating to M.I.T. Case No. 12967W, "Method for Screening Libraries
of Enzymes with Improved Catalytic Properties or Altered Substrate Specificity Using Microwells for the Spatial Separation of Cells
Producing the Enzymes", by John Christopher Love and Kerry Routenberg Love; M.I.T. Case No. 13528, "Method for
Diagnosing Allergic Reactions", by Qing Han, John Christopher Love and Vinay Tripuraneni; M.I.T. Case No. 13529, "Method
for Detecting Active and Latent Virally Infected Cells", by Yuan Gong and John Christopher. Love; M.I.T. Case No. 13546,
"Method for Assessing Cytotoxicity of Single Cells", by Boris Julg, John Christopher Love and Navin Varadarajan; and
M.I.T. Case No. 13627, "Composition of an Array of Microwells with an Integrated Microfluidic System", by John
Christopher Love, Eliseo Papa and Craig M. Story, and has the right to grant licenses under said PATENT RIGHTS;

 

WHEREAS, M.I.T. and the Whitehead Institute
of Biomedical Research (hereinafter “Whitehead”) jointly own certain of the PATENT RIGHTS relating to M.I.T. Case
No. 12967W, "Method for Screening Libraries of Enzymes with Improved Catalytic Properties or Altered Substrate Specificity
Using Microwells for the Spatial Separation of Cells Producing the Enzymes", by John Christopher Love and Kerry Routenberg
Love, and have signed a Joint Invention Agreement, effective August 25, 2008, and amended by a First Amendment effective July 29,
2009, that appoints M.I.T. as the sole agent for licensing such PATENT RIGHTS and which has not been terminated and is still in
effect and valid; and

 

    	 

    	 

    

 

WHEREAS, M.I.T. and the General Hospital
Corporation, doing business as Massachusetts General Hospital, (hereinafter “Hospital”) jointly own certain of the
PATENT RIGHTS relating to M.I.T. Case No. 13546, "Method for Assessing Cytotoxicity of Single Cells", by Boris
Julg, John Christopher Love and Navin Varadarajan, and have signed a Joint Invention Administration Agreement, effective December
10, 2010, that appoints M.I.T. as the exclusive agent for licensing such PATENT RIGHTS and which has not been terminated and is
still in effect and valid; and

 

WHEREAS, the President and Fellows of Harvard
College (hereinafter “Harvard”), is the owner of certain of the PATENT RIGHTS relating to M.I.T. Case No. 12393Q,
"Screening Assays and Methods", by John Christopher Love, Hidde L. Ploegh and Jehnna Ronan (Harvard Reference HU-2514)
(the “HARVARD PATENT RIGHTS” as later defined herein); and

 

WHEREAS, M.I.T. and Harvard have signed
an Inter-Institutional Agreement, dated May 17, 2010, and amended by a Letter Amendment dated December 1, 2010, that appoints M.I.T.
as the exclusive agent for licensing the HARVARD PATENT RIGHTS, which has not been terminated and which is still in effect and
binding;

 

WHEREAS, John Christopher Love and Kerry
Routenberg Love, inventors of certain of the PATENT RIGHTS and current employees of M.I.T., have or will shortly acquire equity
in COMPANY, the Conflict Avoidance Statement of John Christopher Love and Kerry Routenberg Love are attached as Exhibits A-1
and A-2 hereto;

 

WHEREAS, John Christopher Love and Kerry
Routenberg Love, inventors of certain of the PATENT RIGHTS, have or will shortly acquire equity in COMPANY not resulting from this
Agreement, the Inventor/Author Acknowledgment of No Equity Distribution in M.I.T.'s institutional equity share of John Christopher
Love and Kerry Routenberg Love are attached as Exhibits B-1 and B-2 hereto;

 

WHEREAS, M.I.T.'s Vice President for Research
has approved that John Christopher Love, an inventor of the PATENT RIGHTS, now holds or shall shortly acquire equity in COMPANY
and that M.I.T. is accepting equity as partial consideration for the rights and licenses granted under this Agreement;

 

WHEREAS, M.I.T., for itself and on behalf
of HARVARD, WHITEHEAD, and HOSPITAL, desires to have the PATENT RIGHTS developed and commercialized to benefit the public and is
willing to grant a license thereunder;

 

    	2

    	 

    

 

WHEREAS, COMPANY has represented to M.I.T.,
to induce M.I.T. to enter into this Agreement, that, subject to the terms and conditions hereof, COMPANY shall commit itself to
a diligent program of exploiting the PATENT RIGHTS so that public utilization shall result therefrom; and

 

WHEREAS, COMPANY desires to obtain a license
under the PATENT RIGHTS upon the terms and conditions hereinafter set forth.

 

NOW, THEREFORE, M.I.T., for itself and on
behalf of the Hospital, Whitehead and Harvard, and COMPANY hereby agree as follows:

 

1. DEFINITIONS.

 

1.1 "AFFILIATE" shall mean
any legal entity (such as a corporation, partnership, or limited liability company) that is controlled by COMPANY. For the purposes
of this definition, the term "control" means (i) beneficial ownership of at least fifty percent (50%) of the voting securities
of a corporation or other business organization with voting securities or (ii) a fifty percent (50%) or greater interest in the
net assets or profits of a partnership or other business organization without voting securities.

 

1.2 “APPARATUS PRODUCT”
shall mean a LICENSED PRODUCT that is a microarray comprising microwells, and that is substantially similar to a product as described
in the HARVARD PATENT RIGHTS, including without limitation claims 5-14 of U.S. Patent Application Serial Number 11/523124 as filed,
and/or M.I.T. Case No. 13627, and which has utility in practicing the methods and processes described in the PATENT RIGHTS.

 

1.3 “COMBINATION PRODUCT”
shall mean a product, including a package of related products sold together as a kit) which contains (i) a component that is a
LICENSED PRODUCT or DISCOVERED PRODUCT; and (ii) one or more essential functional components (“OTHER COMPONENT”)
that are or which could be sold separately and which perform a useful function independent of the LICENSED PRODUCT or DISCOVERED
PRODUCT component, such that the LICENSED PRODUCT or DISCOVERED PRODUCT component can also function independently of the OTHER
COMPONENT. For the purposes of this Agreement, the parties agree that an “OTHER COMPONENT” shall specifically exclude,
without limitation, the following: slides, plastic ware (such as tubes and plates), glassware, water and buffers. Without limiting
the foregoing, an example of a COMBINATION PRODUCT could be (a) a diagnostic panel comprising a DIAGNOSTIC PRODUCT component and
at least one other independent diagnostic biomarker, i.e., the OTHER COMPONENT.

 

    	3

    	 

    

 

1.4 “COMPETING
ORGANIZATION” means any person or organization engaged in, or that anticipates becoming engaged in, researching,
acquiring, producing, distributing, providing investigating, developing, manufacturing, marketing, supervising, licensing or commercializing
a COMPETING PRODUCT OR SERVICE anywhere in the world.

 

1.5           “COMPETING
PRODUCT OR SERVICE” means any product, process, or service of any person or organization other than the COMPANY
or any of its subsidiaries, in existence or under development, (i) which is identical to, substantially the same as, in competition
with, or an adequate substitute for any product, process, or service of the COMPANY or any of its subsidiaries, in existence or
under development or (ii) which is (or could reasonably be anticipated to be) marketed or distributed or is under development to
be marketed or distributed, as to compete with such product, process or service of the Company or any of its subsidiaries.

 

1.6          “CONFIDENTIAL
INFORMATION” shall mean any confidential or proprietary information furnished by one party (the “Disclosing Party”)
to the other party (the “Receiving Party”) in connection with this Agreement, provided that such information is specifically
designated as confidential. Such CONFIDENTIAL INFORMATION shall include, without limitation, any information provided by COMPANY
to M.I.T. pursuant to Section 5.2, or made available to M.I.T. or its auditors pursuant to Section 5.4.

 

1.7       “CORPORATE
PARTNER” shall mean any non-AFFILIATE, non-SUBLICENSEE entity which agrees to compensate, at a minimum including payment
of RESEARCH SUPPORT PAYMENTS, COMPANY or an AFFILIATE or SUBLICENSEE for  COMPANY’s or AFFILIATE’s or SUBLICENSEE’s
practice of the PATENT RIGHTS, LICENSED PRODUCTS, DISCOVERED PRODUCTS and/or LICENSED PROCESSES on behalf of or in collaboration
with such entity, including without limitation for (i) discovery and development activities for DISCOVERED PRODUCTS, and/or (ii)
identification and/or characterization of drug candidates, or drug response analysis.

 

1.8 “CORPORATE PARTNER INCOME”
shall mean any payments that COMPANY or an AFFILIATE or SUBLICENSEE receives from a CORPORATE PARTNER in consideration of any of
the rights described in Section 1.4, including without limitation upfront fees, milestone and bonus payments (including without
limitation milestone payments related to LICENSED PRODUCTS, LICENSED PROCESSES and/or DISCOVERED PRODUCTS), agreement maintenance
fees, and other payments, but specifically excluding (i) royalties on NET SALES due under Section 4.1(c), and (ii) RESEARCH SUPPORT
PAYMENTS.

 

    	4

    	 

    

 

1.9 “DIAGNOSTIC PRODUCT”
shall mean a LICENSED PRODUCT or DISCOVERED PRODUCT that is used or intended for use (i) in the diagnosis and/or prognosis of diseases
or conditions, and/or (ii) for the medical management of disease or conditions, including without limitation the determination
(whether by selection or exclusion) of a particular intervention for the prevention and/or treatment of disease, in humans, including
without limitation application specific reagents and kits.

 

1.10 “DISCOVERED PRODUCT”
shall mean any product that, in whole or in part, is discovered, identified, selected or determined to have utility in whole or
in part by the use of LICENSED PRODUCTS and/or LICENSED PROCESSES, including without limitation the use of a screening method or
assay covered by one or more VALID CLAIMS of the PATENT RIGHTS. For example, in the case of THERAPEUTIC PRODUCTS and DIAGNOSTIC
PRODUCTS, DISCOVERED PRODUCTS shall include, without limitation, a previously known product for which LICENSED PRODUCTS and/or
LICENSED PROCESSES are used to identify criteria for either selecting or deselecting groups and/or individuals for a particular
use of such product, thereby clinically increasing the efficacy and/or safety of the use of such product. For any DISCOVERED PRODUCT
that also falls within the definition of LICENSED PRODUCT, then such DISCOVERED PRODUCT shall be deemed a LICENSED PRODUCT for
the purposes of this Agreement rather than a DISCOVERED PRODUCT.

 

1.11 "EXCLUSIVE PERIOD"
shall mean the period of time set forth in Section 2.2.

 

1.12 "FIELD" shall mean
all fields.

 

1.13 “GENERIC LAUNCH DATE”
shall mean, on a country-by-country basis, the date of the first sale by a third party, for end use or consumption by a patient,
of a GENERIC PRODUCT in the subject country.

 

1.14      “GENERIC
PRODUCT” shall mean, on a country-by-country and DISCOVERED PRODUCT-by-DISCOVERED PRODUCT basis, a therapeutic product
that (i) in the instance of a small molecule chemical drug, has the same composition of matter as and is bioequivalent to an approved
DISCOVERED PRODUCT, or (ii) in the instance of a biological drug, is a biosimilar of and interchangeable with an approved DISCOVERED
PRODUCT, and in each instance is intended for the same indication as an approved DISCOVERED PRODUCT, and which has been approved
for marketing and/or sale under an Abbreviated New Drug Application (or equivalent, including without limitation for biosimilar
biological products) as a generic or follow-on biologic product by the regulatory authorities, and which could not have been sold
or with respect to which a license would have been required to be obtained from COMPANY, if patent or other exclusivity rights
(for example, data exclusivity) covering the approved DISCOVERED PRODUCT would have been in full force and effect.

 

    	5

    	 

    

 

1.15 “HARVARD PATENT RIGHTS”
shall mean Harvard’s rights in:

 

(a) U.S. Patent Application No. 11/523,124;

 

(b) any patent or patent application
that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of the patent
application identified in (a);

 

(c) any patents issuing on any of the
patent applications identified in (a) or (b), including any reissues, renewals, reexaminations, substitutions or extensions thereof;

 

(d) any claim of a continuation-in-part
application or patent that is entitled to the priority date of, and is directed specifically to subject matter specifically described
in, at least one of the patents or patent applications identified in (a), (b) or (c); and

 

(e) any foreign counterpart (including
PCTs) of any of the patents or patent applications identified in (a), (b) or (c) or of the claims identified in (d).

 

1.16 “IMPROVEMENT” shall
mean any patentable invention which is:

 

(i) arising
from research performed solely in the laboratory of John Christopher Love at M.I.T; and

 

(ii) disclosed
to the M.I.T. Technology Licensing Office within two (2) years of the EFFECTIVE DATE; and 

 

(iii)
dominated by claims of the PATENT RIGHTS other than the HARVARD PATENT RIGHTS licensed under this Agreement and listed in Appendix
A as of the EFFECTIVE DATE; and 

 

(iv) available for licensing after satisfaction
of any rights granted to sponsors of the research leading to such invention.

 

1.17      “IND” means an Investigational New Drug Application (as defined in Title 21 of the United States
Code of Federal Regulations, as amended from time to time) filed or to be filed with the United States Food and Drug Administration,
or any successor agency thereto, with regard to any THERAPEUTIC PRODUCT, and any foreign equivalent thereof.

 

    	6

    	 

    

 

1.18   "LICENSED
PRODUCT" shall mean any product that, in whole or in part:

 

(i)          absent
the license granted hereunder, would infringe one or more VALID CLAIMS of the PATENT RIGHTS; or

 

(ii)          is
manufactured by using a LICENSED PROCESS or that, when used, practices a LICENSED PROCESS in each instance as defined in Section
1.19(i).

 

1.19 "LICENSED PROCESS"
shall mean any process:

 

(i)          
that, absent the license granted hereunder, would infringe one or more VALID CLAIMS of the PATENT RIGHTS; or

 

(ii)         which
uses a LICENSED PRODUCT as defined in Section 1.18(i).

 

1.20 “LICENSED SERVICE”
shall mean: (i) any provision of services to a third party using LICENSED PRODUCTS, DISCOVERED PRODUCTS and/or LICENSED PROCESSES;
and/or (ii) any practice of the PATENT RIGHTS on behalf of a third party, including without limitation research, discovery and/or
development of DISCOVERED PRODUCTS, but which does not include payment of RESEARCH SUPPORT PAYMENTS.

 

1.21 "NET SALES" shall
mean the gross amount billed by COMPANY and its AFFILIATES and SUBLICENSEES and CORPORATE PARTNERS for LICENSED PRODUCTS and DISCOVERED
PRODUCTS, less the following:

 

(i) customary trade, quantity, or cash discounts
to the extent actually allowed and taken;

 

(ii) amounts repaid or credited, or allowances
by reason of rejection, recalls or returns;

 

(iii) to the extent separately stated on purchase
orders, invoices, or other documents of sale, any taxes, duties, tariffs or other governmental charges levied on the production,
sale, transportation, delivery, or use of a LICENSED PRODUCT or DISCOVERED PRODUCT which is paid by or on behalf of COMPANY;

 

(iv) outbound transportation costs prepaid
or allowed and costs of insurance in transit;

 

(v)
discounts or rebates or other payments required by law to be made under Medicaid, Medicare or other governmental special
medical assistance programs, to the extent actually allowed and taken; and

 

(vi) amounts written off by reason of uncollectible
bad debt, but not to exceed * of the gross amount billed by COMPANY and its AFFILIATES and SUBLICENSEES for LICENSED PRODUCTS and
DISCOVERED PRODUCTS in a given REPORTING PERIOD.

 

    	7

    	 

    

 

No deductions shall be made for commissions
paid to individuals whether they be with independent sales agencies or regularly employed by COMPANY and on its payroll, or for
cost of collections. NET SALES shall occur on the earlier of (1) ninety (90) days from the date of billing for a LICENSED PRODUCT
or DISCOVERED PRODUCT, or (2) the date of receipt of payment for such LICENSED PRODUCT or DISCOVERED PRODUCT. If a LICENSED PRODUCT
or a DISCOVERED PRODUCT is distributed at a discounted price that is substantially lower than the customary price charged by COMPANY,
or distributed for non-cash consideration (whether or not at a discount), NET SALES shall be calculated based on the non-discounted
amount of the LICENSED PRODUCT or DISCOVERED PRODUCT charged to an independent third party during the same REPORTING PERIOD or,
in the absence of such sales, on the fair market value of the LICENSED PRODUCT or DISCOVERED PRODUCT. NET SALES shall not include
sales or transfers of reasonable amounts of LICENSED PRODUCTS or DISCOVERED PRODUCTS without consideration for use in clinical
trials or compassionate, named patient, indigent patient or similar uses, or for demonstration or proof of principal purposes.

 

Non-monetary consideration shall not be accepted
by COMPANY, any AFFILIATE, or any SUBLICENSEE for any LICENSED PRODUCTS or DISCOVERED PRODUCTS without the prior written consent
of M.I.T., which shall not be unreasonably withheld or delayed. In the event that non-monetary consideration is received for LICENSED
PRODUCTS or DISCOVERED PRODUCTS, NET SALES shall be calculated based on the fair market value of such non-monetary consideration,
including all elements of such consideration.

 

In the event that COMPANY or its AFFILIATES
or SUBLICENSEES use or dispose of a LICENSED PRODUCT or DISCOVERED PRODUCT in the provision of a LICENSED SERVICE, such use or
disposal shall be accounted for in SERVICE INCOME and not in NET SALES.

 

For clarification, any amounts billed by COMPANY
and its AFFILIATES and SUBLICENSEES for LICENSED PROCESSES, including, without limitation, the performance of LICENSED PROCESSES
in the provision of a service shall be considered SERVICE INCOME not NET SALES.

 

In the event that a LICENSED PRODUCT or DISCOVERED
PRODUCT is sold as a COMBINATION PRODUCT, NET SALES, for the purposes of determining royalty payments on the COMBINATION PRODUCT
under Sections 4.1(c)(i), 4.1(c)(ii)(A), 4.1(c)(iii)(A), 4.1(c)(iv)(A) and 4.1(c)(v)(A), shall mean the gross amount billed for
the COMBINATION PRODUCT less the deductions set forth in clauses (i) – (vi) of this Section above, multiplied by a proration
factor that is determined as follows:

 

    	8

    	 

    

 

(a) If all components of the COMBINATION
PRODUCT were sold separately during the same or immediately preceding REPORTING PERIOD, the proration factor shall be determined
by the formula [A / (A+B)], where A is the average gross sales price of all LICENSED PRODUCT or DISCOVERED PRODUCT components during
such period when sold separately from the other biologically active ingredient(s), and B is the average gross sales price of the
other biologically active ingredient(s) during such period when sold separately from the LICENSED PRODUCT or DISCOVERED PRODUCT
components; or

 

(b) If all components of the COMBINATION
PRODUCT were not sold separately during the same or immediately preceding REPORTING PERIOD, the proration factor shall be determined
by M.I.T. and COMPANY in good faith negotiations, taking into account, without limitation, the relative value contributed by each
component. In the event that MIT and the COMPANY are unable to agree upon a proration factor within one hundred and twenty (120)
days of first commercial sale of the COMBINATION PRODUCT, then the COMPANY, at its own expense, shall have the right to refer the
determination of such proration factor to an independent third party expert mutually acceptable to the parties, such acceptance
not to be unreasonably withheld or delayed, within three (3) months (the “COMPANY Valuation”). If M.I.T. disputes the
appropriateness of the COMPANY Valuation, M.I.T., at its own expense, shall have the right to refer the determination of such proration
factor to an independent third party expert mutually acceptable to the parties, such acceptance not to be unreasonably withheld
or delayed, within three (3) months (the “M.I.T. Valuation”), and the average of the COMPANY Valuation and the M.I.T.
Valuation (or other such valuation mutually agreed to be the parties) shall be used as the proration factor.

 

1.22 “OTHER PRODUCT”
shall mean any LICENSED PRODUCT or DISCOVERED PRODUCT other than an APPARATUS PRODUCT, DIAGNOSTIC PRODUCT, THERAPEUTIC PRODUCT
or VETERINARY PRODUCT.

 

1.23 “PATENT CHALLENGE”
shall mean a challenge to the validity, patentability, enforceability and/or non-infringement of any of the PATENT RIGHTS (as defined
below) or otherwise opposing any of the PATENT RIGHTS.

 

1.24 "PATENT RIGHTS" shall
mean:

 

(i) with respect to M.I.T. Case Nos. 12967W,
13528, 13529, 13546 and 13627:

 

(a)          the
United States and international patents listed on Appendix A;

 

(b)          the
United States and international patent applications and/or provisional applications listed on Appendix A and the resulting
patents;

 

    	9

    	 

    

 

(c)          any
patent applications resulting from the provisional applications listed on Appendix A, and any divisionals, continuations,
continuation-in-part applications, and continued prosecution applications (and their relevant international equivalents) of the
patent applications listed on Appendix A and of such patent applications that result from the provisional applications listed
on Appendix A, to the extent the claims are directed to subject matter specifically described in the patent applications
listed on Appendix A, and the resulting patents;

 

(d)          any
patents resulting from reissues, reexaminations, or extensions (and their relevant international equivalents) of the patents described
in (a), (b), and (c) above; and

 

(e)          international
(non-United States) patent applications and provisional applications filed after the EFFECTIVE DATE and the relevant international
equivalents to divisionals, continuations, continuation-in-part applications and continued prosecution applications of the patent
applications to the extent the claims are directed to subject matter specifically described in the patents or patent applications
referred to in (a), (b), (c), and (d) above, and the resulting patents; and

 

(ii) the HARVARD PATENT RIGHTS.

 

1.25         “PHASE
1 CLINICAL TRIAL” means clinical studies in human subjects to evaluate the safety, toxicity, tolerance, pharmacokinetic
properties, pharmacodynamic properties, dosing interval, maximum tolerated dose, dose ranging, and/or absorption, distribution,
metabolism, excretion (ADME) of a THERAPEUTIC PRODUCT.

 

1.26         “PHASE
2 CLINICAL TRIAL” means clinical studies in human subjects to evaluate proof of concept, proof of mechanism, and/or efficacy
in the targeted patient population, and/or to define the dosing range or safety profile of a THERAPEUTIC PRODUCT.

 

1.27         “PHASE
3 CLINICAL TRIAL” means clinical studies in human subjects to confirm the efficacy, safety, and/or further define targeted
dose of a THERAPEUTIC PRODUCT.

 

1.28         "REPORTING
PERIOD" shall begin on the first day of each calendar quarter and end on the last day of such calendar quarter.

 

1.29         “RESEARCH MARKET”
shall mean non-commercial research conducted at non-profit research institutions and universities.

 

    	10

    	 

    

 

1.30 “RESEARCH SUPPORT PAYMENTS”
shall mean payments to COMPANY or an AFFILIATE or SUBLICENSEE from a CORPORATE PARTNER or SUBLICENSEE for the purposes of funding
the costs of bona fide research and development of LICENSED PRODUCTS, LICENSED PROCESSES or DISCOVERED PRODUCTS and that
are expressly intended only to fund or pay for: (i) the purchase, lease or use of equipment, supplies, products or services, (ii)
the use of employees and/or consultants to achieve a research and/or development goal for LICENSED PRODUCTS, LICENSED PROCESSES
or DISCOVERED PRODUCTS, and (iii) reasonable allocable overhead attributable to the expenses described in (i) and (ii) and determined
in accordance with United States generally accepted accounting principles, as indicated by their inclusion as specific line items
in a written agreement between COMPANY or an AFFILIATE or SUBLICENSEE and the CORPORATE PARTNER or SUBLICENSEE.

 

1.31 “SERVICE INCOME”
shall mean (i) the gross amount billed by COMPANY and its AFFILIATES and SUBLICENSEES for LICENSED SERVICES, including without
limitation LICENSED PROCESSES, and/or (ii) any payments received by COMPANY, an AFFILIATE or SUBLICENSEE, other than payments received
in accordance with clause (i) of this Section, including without limitation upfront or periodic fees, milestone and bonus payments,
royalties, profit and/or revenue sharing and other payments, in consideration of the provision of LICENSED SERVICES. For clarification,
(a) any payments received by COMPANY or an AFFILIATE or SUBLICENSEE from a CORPORATE PARTNER in consideration of the provision
of LICENSED SERVICES to such CORPORATE PARTNER shall be deemed CORPORATE PARTNER INCOME for the purposes of this Agreement, and
(b) any payments received by COMPANY or an AFFILIATE from a SUBLICENSEE in consideration of the provision of LICENSED SERVICES
to such SUBLICENSEE shall be deemed SERVICE INCOME (and not SUBLICENSEE INCOME) for the purposes of this Agreement.

 

If LICENSED SERVICES are
performed or provided at a discounted price that is substantially lower than the customary price charged by COMPANY, or performed
or provided for non-cash consideration (whether or not at a discount), SERVICE INCOME shall be calculated on the non-discounted
amount of the LICENSED SERVICES or on the fair market value of the LICENSED SERVICES, as appropriate.

 

Non-monetary consideration
shall not be accepted by COMPANY, any AFFILIATE, or any SUBLICENSEE for any LICENSED SERVICES without the prior written consent
of M.I.T. In the event that non-monetary consideration is received for LICENSED SERVICES, SERVICE INCOME shall be calculated based
on the fair market value of such non-monetary consideration (including all elements of such consideration), as determined by the
parties in good faith.

 

1.32 "SUBLICENSE INCOME"
shall mean any payments that COMPANY receives from a SUBLICENSEE in consideration of the sublicense of the rights granted COMPANY
and AFFILIATES under Section 2.1, including without limitation license fees, milestone and bonus payments (including without limitation
milestone payments related to LICENSED PRODUCTS, LICENSED PROCESSES and/or DISCOVERED PRODUCTS), license maintenance fees, and
other payments, but specifically excluding (i) royalties on NET SALES due under Section 4.1(c)(ii)(B), 4.1(c)(iii)(B), 4.1(c)(iv)(B)
and 4.1(c)(v)(B), (ii) RESEARCH SUPPORT PAYMENTS, and (iii) payments made as consideration for the issuance of equity or debt securities
of COMPANY at fair market value (excluding amounts in excess of the fair market value of such securities).

 

    	11

    	 

    

 

Consideration for any and all sublicenses
of the PATENT RIGHTS shall be on commercially reasonable terms and conditions. In the event that non-monetary consideration is
received for any sublicense of the PATENT RIGHTS, SUBLICENSE INCOME shall be calculated based on the fair market value of such
non-monetary consideration, including all elements of such consideration.

 

1.33 "SUBLICENSEE" shall
mean any non-AFFILIATE sublicensee of the rights granted COMPANY under Section 2.1. For clarity, a sublicense shall mean (i) any
right granted, license given or agreement entered into by COMPANY to or with another person or entity, under or with respect to
or permitting any use of the PATENT RIGHTS or otherwise granting rights to such person or entity under the rights granted COMPANY
under Section 2.1, (ii) any option or other right granted by COMPANY to any other person or entity to negotiate for or receive
any of the rights described under clause (i), or (iii) any standstill or similar obligation undertaken by COMPANY toward another
person or entity not to grant any of the rights described in clause (i) or (ii) to any third party, in each case regardless of
whether such grant of rights, license given or agreement entered into is referred to or is described as a sublicense.

 

1.34 "TERM" shall mean
the term of this Agreement, which shall commence on the EFFECTIVE DATE and shall remain in effect until the expiration or abandonment
of all issued patents and filed patent applications within the PATENT RIGHTS, unless earlier terminated in accordance with the
provisions of this Agreement.

 

1.35 "TERRITORY" shall
mean worldwide.

 

1.36 “THERAPEUTIC PRODUCT”
shall mean a LICENSED PRODUCT or DISCOVERED PRODUCT that is used or intended for use in the treatment and/or prevention of human
disease, including, without limitation, therapeutic and prophylactic vaccines.

 

1.37 “VALID CLAIM” shall
mean (a) a claim of an issued and unexpired patent within the PATENT RIGHTS, which claim has not been revoked or found to be unpatentable,
invalid or unenforceable by an unreversed and unappealable decision of a court or other governmental agency of competent jurisdiction;
or (b) a claim set forth in an application within the PATENT RIGHTS that has been filed in good faith and that has not been abandoned
or finally rejected in a decision that is unappealable or unappealed within the time allowed for appeal.  The invalidity of
a particular claim in one or more countries shall not invalidate such claim in the remaining countries of the TERRITORY.

 

    	12

    	 

    

 

1.38 “VETERINARY PRODUCT”
shall mean a LICENSED PRODUCT or DISCOVERED PRODUCT that is used or intended for use in (i) the diagnosis and/or prognosis of disease
in non-human animals, and/or the determination (whether by selection or exclusion) of a particular intervention for the prevention
and/or treatment of disease, including without limitation application specific reagents and kits, and/or (ii) the treatment and/or
prevention of disease in non-human animals, including without limitation therapeutic and prophylactic vaccines.

 

2. GRANT
OF RIGHTS.

 

2.1 License Grants. Subject to the
terms of this Agreement, M.I.T., for itself and on behalf of HARVARD, HOSPITAL and WHITEHEAD, hereby grants to COMPANY and its
AFFILIATES for the TERM a royalty-bearing license under the PATENT RIGHTS to develop, make, have made, use, sell, offer to sell,
lease, and import LICENSED PRODUCTS in the FIELD in the TERRITORY and to develop and perform LICENSED PROCESSES in the FIELD in
the TERRITORY.

 

2.2 Exclusivity.

 

(a) In order to establish an exclusive period
for COMPANY, M.I.T, agrees that, subject to Article 10 and Sections 2.2(b), 2.2(c) and 2.6, it shall not grant any other license
under the PATENTS RIGHTS to develop, make, have made, use, sell, offer to sell, lease or import LICENSED PRODUCTS in the FIELD
in the TERRITORY or to develop or perform LICENSED PROCESSES in the FIELD in the TERRITORY during the TERM (the "EXCLUSIVE
PERIOD"), unless sooner terminated as provided in this Agreement, including as set forth in Section 10(ii)(b).

 

(b) Pre-Existing License to the HARVARD
PATENT RIGHTS. COMPANY acknowledges that the license granted hereunder is subject to a pre-existing non-exclusive, worldwide,
non-transferable license, without the right to grant sublicenses, granted by HARVARD to one third party under the HARVARD PATENT
RIGHTS to practice the methods claimed in the HARVARD PATENT RIGHTS solely for research, discovery and/or development of biological
and/or pharmaceutical products

 

    	13

    	 

    

 

(c) Notwithstanding anything to the contrary
in Section 3.1, in the event that COMPANY (or an AFFILIATE or SUBLICENSEE) has failed any of its obligations under Sections 3.1(g),
3.1(h) or 3.1(i), then M.I.T., at its sole discretion, shall have the right to grant non-exclusive or exclusive licenses under
the PATENT RIGHTS to any third party to make, have made, use, sell, lease and import APPARATUS PRODUCTS for the RESEARCH MARKET
in the TERRITORY during the TERM. Upon the effective date of any such license, COMPANY’s and AFFILIATE’s (and SUBLICENSEE’s,
as applicable) rights to make, have made, use, sell, lease and import APPARATUS PRODUCTS for the RESEARCH MARKET in the TERRITORY
during the TERM shall terminate.

 

2.3 Option to IMPROVEMENTS.

 

(a)          If
an invention is identified as an IMPROVEMENT, subject to any obligation of M.I.T. to third parties, M.I.T. agrees to grant to COMPANY
the option (each, an “OPTION”) to add any IMPROVEMENT to this Agreement, by amendment, in accordance with this Section
2.3. Such OPTION shall include solely M.I.T.’s interests in IMPROVEMENTS, and shall not include ownership rights of any third
party in IMPROVEMENTS.

 

(b)          M.I.T.
shall promptly notify COMPANY in writing of any such IMPROVEMENT, simultaneously furnishing COMPANY a copy of the invention disclosure
and/or any related patent application(s). Such invention disclosure and any related patent application(s) shall be kept confidential
by COMPANY. Notwithstanding the foregoing, M.I.T. shall be under no obligation to file a patent application for any IMPROVEMENT
unless COMPANY exercises its option with respect to such IMPROVEMENT.

 

(c)          COMPANY
may exercise its OPTION to add such IMPROVEMENT to the PATENT RIGHTS by notifying M.I.T. thereof in writing within ninety (90)
days after M.I.T.’s notice of such IMPROVEMENT (the “OPTION PERIOD”). For each IMPROVEMENT so elected, COMPANY
shall pay an Improvement Addition Fee of *, and shall be responsible for the payment
of fees and costs relating to the filing, prosecution and maintenance of the PATENT RIGHTS covering such IMPROVEMENT.

 

(d)          If
COMPANY does not exercise its OPTION within the OPTION PERIOD, M.I.T. shall be free to license its rights to such IMPROVEMENT to
any third party.

 

    	14

    	 

    

 

2.4 Sublicenses. COMPANY shall have
the right to grant sublicenses, either exclusive or non-exclusive, of its rights under Section 2.1 only during the EXCLUSIVE PERIOD
.. Such sublicenses may extend past the expiration date of the EXCLUSIVE PERIOD, but any exclusivity of such sublicense shall expire
upon the expiration of the EXCLUSIVE PERIOD. COMPANY shall incorporate terms and conditions into its sublicense agreements sufficient
to enable COMPANY to comply with this Agreement. COMPANY shall also include provisions in all sublicenses to provide that in the
event that SUBLICENSEE brings a PATENT CHALLENGE against M.I.T. (and/or WHITEHEAD, HARVARD or HOSPITAL) or assists another party
in bringing a PATENT CHALLENGE against M.I.T. (and/or WHITEHEAD, HARVARD or HOSPITAL) (except as required under a court order or
subpoena) then COMPANY may terminate the sublicense. In addition, any sublicense that contains a grant of rights under the HARVARD
PATENT RIGHTS shall state that the license granted therein in subject to a pre-existing license to the HARVARD PATENT RIGHTS of
the scope described in Section 2.2(b). COMPANY shall promptly furnish M.I.T. with a fully signed photocopy of any sublicense agreement,
and M.I.T. may send a copy thereof to HHMI in confidence. Upon termination of this Agreement for any reason, any SUBLICENSEE not
then in default shall have the right to seek a license from M.I.T. M.I.T. agrees to negotiate in good faith such licenses in good
faith under reasonable terms and conditions.

 

2.5 U.S. Manufacturing. COMPANY agrees
that any LICENSED PRODUCTS used or sold in the United States will be manufactured substantially in the United States to the extent
required by 35 U.S.C. §§200-212 and the regulations promulgated thereunder, as amended (the “BAYH-DOLE ACT”)
or any successor statutes or regulations. If COMPANY desires to seek a waiver of such requirements, upon request of COMPANY, M.I.T.
agrees to provide reasonable assistance in the application process for such waiver, however issuance of any such waiver is not
guaranteed.

 

2.6 Retained Rights.

 

(a)          Research and Educational Use.
M.I.T., WHITEHEAD, HARVARD and HOSPITAL retain the right on behalf of themselves to practice under the PATENT RIGHTS for research,
teaching, and educational purposes. In addition, M.I.T., WHITEHEAD, HARVARD and HOSPITAL retain the right on behalf of all other
non-profit research institutions to practice under the PATENT RIGHTS for non commercial research, teaching, and educational purposes
only.

 

    	15

    	 

    

 

(b)          Federal Government. COMPANY
acknowledges that the U.S. federal government retains a royalty-free, non-exclusive, non-transferable license to practice any government-funded
invention claimed in any PATENT RIGHTS as set forth in BAYH-DOLE ACT, or any successor statutes or regulations.

 

(c)          COMPANY
acknowledges that the Third Party retains a license under the HARVARD PATENT RIGHTS of the scope described in Section 2.2(b).

 

(d)          
Encumbrances for Sponsors of Research at M.I.T.

 

(i) M.I.T. retains the right to grant to
an existing third party industrial sponsor of research in the laboratory of John Christopher Love a non-exclusive, worldwide license
under M.I.T. Case No. 12967W and/or M.I.T. Case No. 13627 of the PATENT RIGHTS. This non-exclusive license shall be granted only
to the extent necessary to allow the sponsor to practice new inventions that arise from the sponsored research.

 

(ii) As the Subrecipient of federal funds
from a Prime Recipient institution, M.I.T. retains the right to grant to the Prime Recipient a non-exclusive, worldwide license
under M.I.T. Case No. 12393Q, M.I.T. Case No. 13529 and/or M.I.T. Case No. 13627 of the PATENT RIGHTS solely for the purpose
of and only to the extent required to meet the Prime Recipient’s obligations to the Federal Government under its Prime Award.

 

(e)          HHMI.
COMPANY acknowledges that the PATENT RIGHTS were developed, at least in part, by employees of HHMI, and that HHMI has a paid-up,
non-exclusive, irrevocable license to use the PATENT RIGHTS for its research purposes, but with no right to assign or sublicense
(the “HHMI License”). This Agreement is explicitly made subject to the HHMI License.

 

(f)          Diagnostics.
HOSPITAL retains the right for laboratories within HOSPITAL and its affiliates to practice LICENSED PRODUCTS and LICENSED PROCESSES
in the diagnostic filed for public use and benefit.

 

2.7 No Additional Rights. Nothing
in this Agreement shall be construed to confer any rights upon COMPANY by implication, estoppel, or otherwise as to any technology
or patent rights of M.I.T. or HARVARD or any other entity other than the PATENT RIGHTS, regardless of whether such technology or
patent rights shall be dominant or subordinate to any PATENT RIGHTS.

 

    	16

    	 

    

 

3. COMPANY
Diligence Obligations.

 

3.1 Diligence Requirements. COMPANY
shall use commercially reasonable diligent efforts, or shall cause its AFFILIATES to use commercially reasonable diligent efforts,
to develop, either by itself or through SUBLICENSEES or CORPORATE PARTNERS, LICENSED PRODUCTS, DISCOVERED PRODUCTS or LICENSED
PROCESSES and to introduce LICENSED PRODUCTS, DISCOVERED PRODUCTS or LICENSED PROCESSES into the commercial market;. Specifically,
COMPANY or AFFILIATE shall use commercially reasonable efforts to fulfill the following obligations:

 

(a)          Within * after the EFFECTIVE DATE,
COMPANY shall furnish M.I.T. with a written research and development plan describing the major tasks to be achieved in order to
bring to market a LICENSED PRODUCT, DISCOVERED PRODUCT or a LICENSED PROCESS, specifying the number of staff and other resources
to be devoted to such commercialization effort.

 

(b)          Within * after the end of each calendar
year, COMPANY shall furnish M.I.T. with a written report (consistent with Section 5.1(a)) on the progress of its efforts during
the immediately preceding calendar year to develop and commercialize LICENSED PRODUCTS, DISCOVERED PRODUCTS or LICENSED PROCESSES.
The report shall also contain a discussion of intended efforts and sales projections for the year in which the report is submitted.

 

(c)          COMPANY
shall raise at least * from the sale of COMPANY'S equity securities for its own account.

 

(d)          In
the aggregate, COMPANY shall raise at least * from a combination of one or more of the following: (i) the sale of Company's equity
securities for its own account, (ii) research and development funds, license fees and/or other payments from CORPORATE PARTNERS
and/or SUBLICENSEES, and (iii) grants from government and non-government sources.

 

(e)          In
the aggregate, COMPANY shall raise at least * from a combination of one or more of the following: (i) the sale of Company's equity
securities for its own account, (ii) research and development funds, license fees and/or other payments from CORPORATE PARTNERS
and/or SUBLICENSEES, (iii) grants from government and non-government sources, and NET SALES.

 

    	17

    	 

    

 

(f)          COMPANY
or an AFFILIATE shall expend at least the amounts set forth below on research and development of LICENSED PRODUCTS, LICENSED PROCESSES
and/or DISCOVERED PRODUCTS in each calendar year (pro-rated for partial years) beginning in 2011 and ending with the first commercial
sale of a THERAPEUTIC PRODUCT or DIAGNOSTIC PRODUCT by COMPANY or an AFFILIATE:

 

	2011	*
	2012	*
	2013 and every year thereafter	*

 

(g)          Within
* of the EFFECTIVE DATE COMPANY or an AFFILIATE or SUBLICENSEE shall develop a prototype of an APPARATUS PRODUCT for the RESEARCH
MARKET (“PROTOTYPE RELEASE DATE”) , and permit an in-plant inspection by M.I.T. on or before *, and thereafter permit
in-plant inspections by M.I.T. at regular intervals with at least one (1) year between each such inspection, solely for the purpose
of the reviewing the activity of the COMPANY with respect to this Agreement.

 

(h)          Within
* of the PROTOTYPE RELEASE DATE, COMPANY or an AFFILIATE or SUBLICENSEE shall make an APPARATUS PRODUCT commercially available
to the RESEARCH MARKET, and thereafter shall continue to make APPARATUS PRODUCT available at commercially reasonable cost to meet
the reasonable commercial demand of the RESEARCH MARKET. All APPARTUS PRODUCTS shall be subject to quality control testing to ensure
product performance in accordance with stated product specifications. Any time after first commercial sale, M.I.T. reserves the
right to test APPARTUS PRODUCTS at random intervals to assure that quality standards have been maintained.

 

(i)          COMPANY
or an AFFILIATE or SUBLICENSEE shall make APPARATUS PRODUCTS available for use by non-profit research institutions without restrictions,
for example, without reach-through royalty rights to discoveries made through use of LICENSED PRODUCTS and LICENSED PROCESSES,
other than the restrictions set forth in Appendix C.

 

    	18

    	 

    

 

(j)          COMPANY
or an AFFILIATE shall enter into at least * sublicenses and/or CORPORATE PARTNER agreements for the development of THERAPEUTIC
PRODUCTS and/or DIAGNOSTIC PRODUCTS by *.

 

(k)          In
the aggregate, COMPANY or an AFFILIATE shall enter into at least * sublicenses and/or CORPORATE PARTNER agreements for the development
of LICENSED PRODUCTS and/or DIAGNOSTIC PRODUCTS by *.

 

(l)          Within
* after the EFFECTIVE DATE, COMPANY or an AFFILIATE shall initiate studies using human derived samples leading to the identification
of THERAPEUTIC PRODUCT candidates.

 

(m)          Within
* of the EFFECTIVE DATE, COMPANY or an AFFILIATE or its SUBLICENSEE or CORPORATE PARTNER shall file an IND on THERAPEUTIC PRODUCT.

 

(n)          Within
* of the EFFECTIVE DATE, COMPANY or an AFFILIATE ,SUBLICENSEE or CORPORATE PARTNER shall commence a PHASE 2 CLINICAL TRIAL of a
THERAPEUTIC PRODUCT.

 

(o)          Within
* of the EFFECTIVE DATE, COMPANY or an AFFILIATE, SUBLICENSEE or CORPORATE PARTNER shall make a first commercial sale of a THERAPEUTIC
PRODUCT.

 

(p)          Within
* of the EFFECTIVE DATE, COMPANY or an AFFILIATE shall initiate studies using human patient-derived samples for the purposes of
discovering DIAGNOSTIC PRODUCT candidates.

 

(q)          Within
* of the EFFECTIVE DATE, COMPANY or an AFFILIATE or a SUBLICENSEE or CORPORATE PARTNER shall initiate clinical studies in support
of obtaining regulatory approval of a DIAGNOSTIC PRODUCT.

 

(r)          Within
* of the EFFECTIVE DATE, COMPANY or an AFFILIATE or CORPORATE PARTNER or SUBLICENSEE shall make a first commercial sale of a DIAGNOSTIC
PRODUCT.

 

    	19

    	 

    

 

In
the event that COMPANY (or an AFFILIATE) has failed to fulfill any of its obligations under this Section 3.1, then M.I.T. may treat
such failure, after the expiration of any applicable cure periods, as a material breach in accordance with Section 12.3(b). Notwithstanding
the foregoing, in the event that COMPANY anticipates a failure to meet an obligation in Section 3.1(m), (n), (o), (q) or
(r) due to unexpected technical, adverse events or regulatory difficulties COMPANY will promptly advise M.I.T. in writing, and
representatives of each party will meet to review the reasons for anticipated failure and discuss in good faith a potential revision
to the diligence schedule. COMPANY and M.I.T. will enter into a written amendment to this Agreement with respect to any mutually
agreed upon change(s) to the relevant obligation.

 

4. ROYALTIES
AND PAYMENT TERMS.

 

4.1 Consideration for Grant of Rights.

 

(a)          License Issue Fee and Patent Cost
Reimbursement. COMPANY shall pay to M.I.T. on the EFFECTIVE DATE a license issue fee of *. In addition, in accordance with
Section 6.3, COMPANY shall reimburse M.I.T. and HARVARD, respectively, for their actual expenses incurred as of the EFFECTIVE DATE
in connection with obtaining the PATENT RIGHTS. These payments are nonrefundable.

 

(b)          
License Maintenance Fees. COMPANY shall pay to M.I.T. the following license maintenance fees on the dates set forth below:

 

	January 1, 2012	 	$	15,000	 
	January 1, 2013	 	$	20,000	 
	January 1, 2014	 	$	25,000	 
	January 1, 2015	 	$	30,000	 
	January 1, 2016	 	$	40,000	 
	January 1, 2017	 	$	50,000	 
	and each January 1 of every year thereafter	 	$	50,000	 

 

This annual license maintenance fee is nonrefundable;
however, the license maintenance fee may be credited to running royalties subsequently due on NET SALES earned during the same
calendar year, if any. License maintenance fees paid in excess of running royalties due in such calendar year shall not be creditable
to amounts due for future years.

 

    	20

    	 

    

 

(c)          
Running Royalties.

 

(i) Running Royalties on NET SALES of
APPARATUS PRODUCTS.

 

(A) COMPANY shall pay to M.I.T. a running
royalty of * of NET SALES of APPARATUS PRODUCTS by COMPANY and AFFILIATES.

 

(B)
COMPANY shall pay to M.I.T. a running royalty on NET SALES of APPARTUS PRODUCTS by SUBLICENSEES of[the greater of: (i) * of any
payments received by COMPANY and AFFILIATES from SUBLICENSEES in consideration of NET SALES of APPARATUS PRODUCTS by SUBLICENSEES
(including, without limitation, royalty payments, profit sharing, and other revenue sharing based on sales of APPARATUS PRODUCTS),
or (ii) * of NET SALES of APPARATUS PRODUCTS by SUBLICENSEES.

 

(ii) Running Royalties on NET SALES of
DIAGNOSTIC PRODUCTS.

 

(A) COMPANY shall pay to M.I.T. a running
royalty of * of NET SALES of DIAGNOSTIC PRODUCTS by COMPANY and AFFILIATES.

 

(B) COMPANY shall pay to M.I.T. a running
royalty of * of any payments received by COMPANY and AFFILIATES from SUBLICENSEES and CORPORATE PARTNERS in consideration of NET
SALES of DIAGNOSTIC PRODUCTS by SUBLICENSEES and CORPORATE PARTNERS (including without limitation royalty payments, profit sharing,
and other revenue sharing based on sales of DIAGNOSTIC PRODUCTS).

 

(iii) Running Royalties on NET SALES
of THERAPEUTIC PRODUCTS.

 

(A) COMPANY shall pay to M.I.T. a running
royalty of * of NET SALES of THERAPEUTIC PRODUCTS by COMPANY and AFFILIATES.

 

(B) COMPANY shall pay to M.I.T. a running
royalty of * of any payments received by COMPANY and AFFILIATES from SUBLICENSEES and CORPORATE PARTNERS in consideration of NET
SALES of THERAPEUTIC PRODUCTS by SUBLICENSEES and CORPORATE PARTNERS (including without limitation royalty payments, profit sharing,
and other revenue sharing based on sales of THERAPEUTIC PRODUCTS).

 

    	21

    	 

    

 

(iv) Running Royalties on NET SALES of
VETERINARY PRODUCTS.

 

(A) COMPANY shall pay to M.I.T. a running
royalty of * of NET SALES of VETERINARY PRODUCTS by COMPANY and AFFILIATES.

 

(B) COMPANY shall pay to M.I.T. a running
royalty of * of any payments received by COMPANY and AFFILIATES from SUBLICENSEES and CORPORATE PARTNERS in consideration of NET
SALES of VETERINARY PRODUCTS by SUBLICENSEES and CORPORATE PARTNERS (including without limitation royalty payments, profit sharing,
and other revenue sharing based on sales of VETERINARY PRODUCTS).

 

(v) Running Royalties on NET
SALES of OTHER PRODUCTS.

 

(A) COMPANY shall pay to M.I.T. a running
royalty of * of NET SALES of OTHER PRODUCTS by COMPANY and AFFILIATES.

 

(B) COMPANY shall pay to M.I.T. a running
royalty of * of any payments received by COMPANY and AFFILIATES from SUBLICENSEES and CORPORATE PARTNERS in consideration of NET
SALES of OTHER PRODUCTS by SUBLICENSEES and CORPORATE PARTNERS (including without limitation royalty payments, profit sharing,
and other revenue sharing based on sales of OTHER PRODUCTS).

 

Running royalties shall be payable for each
REPORTING PERIOD and shall be due to M.I.T. within sixty (60) days of the end of each REPORTING PERIOD.

 

(vi) For the convenience of the parties,
in recognition of the value of the PATENT RIGHTS, LICENSED PRODUCTS and LICENSED PROCESSES in identifying DISCOVERED PRODUCTS,
and in the time it takes to bring DISCOVERED PRODUCTS to market, COMPANY agrees to pay royalties under Sections 4.1(c)(ii)(A),
4.1(c)(iii)(A), 4.1(c)(iv)(A) and 4.1(c)(v)(A) on each DISCOVERED PRODUCT identified and/or discovered during the TERM for * after
first commercial sale of each DISCOVERED PRODUCT. The obligation to pay running royalties on each DISCOVERED PRODUCT under this
Section 4.1(c) shall survive termination of this agreement as specified in Section 12.6(a). For clarification, COMPANY shall be
obligated to pay running royalties on each LICENSED PRODUCT under Sections 4.1(c)(i), 4.1(c)(ii)(A), 4.1(c)(iii)(A), 4.1(c)(iv)(A)
and 4.1(c)(v)(A) during the TERM of this Agreement.

 

    	22

    	 

    

 

(vii) Reduction of Royalties in the Event
of GENERIC PRODUCT Competition. In the event that, on a country-by-country and DISCOVERED PRODUCT-by-DISCOVERED PRODUCT basis,
there is GENERIC PRODUCT on the market for which prescriptions constitute greater than * of the combined prescriptions of such
GENERIC PRODUCT and the equivalent DISCOVERED PRODUCT, in any REPORTING PERIOD, as measured by an independent, commercially available,
reliable method of tracking such prescriptions (“GENERIC PRODUCT COMPETITION”), COMPANY may provide written notice
of such GENERIC PRODUCT COMPETITION to M.I.T. and the parties agree thereafter to discuss in good faith a reduction in royalties
to be paid by COMPANY to M.I.T. under Section 4.1(c)(iii)(A) for such DISCOVERED PRODUCT so long as such GENERIC PRODUCT COMPETITION
continues; provided, however, that in no event shall the royalty payments under Section 4.1(c)(iii)(A), when aggregated with any
other offsets and credits allowed under this Agreement, be less than * of NET SALES of such DISCOVERED PRODUCT in any REPORTING
PERIOD. The parties shall enter into a written amendment to this Agreement with respect to any mutually agreed upon changes to
the relevant royalty obligation.

 

(d)          
Sharing of SUBLICENSE INCOME. COMPANY shall pay M.I.T. a total of * of all SUBLICENSE INCOME received by. Such amount shall
be payable for each REPORTING PERIOD and shall be due to M.I.T. within sixty (60) days of the end of each REPORTING PERIOD.

 

(e)          
Sharing of CORPORATE PARTNER INCOME.

 

(i)          COMPANY
shall pay M.I.T. a total of * of all CORPORATE PARTNER INCOME received by COMPANY, and AFFILIATES. Such amount shall be payable
for each REPORTING PERIOD and shall be due to M.I.T. within sixty (60) days of the end of each REPORTING PERIOD.

 

(ii)         COMPANY
shall pay to M.I.T. a total of * of any payments received by COMPANY from SUBLICENSEES in consideration of CORPORATE PARTNER INCOME
received by SUBLICENSEES.

 

    	23

    	 

    

 

(f)          Sharing
of SERVICE INCOME. COMPANY shall pay M.I.T. a total of * of all SERVICE INCOME received by COMPANY, AFFILIATES and SUBLICENSEES.
Such amount shall be payable for each REPORTING PERIOD and shall be due to M.I.T. within sixty (60) days of the end of each REPORTING
PERIOD. Notwithstanding the foregoing, if COMPANY, in its reasonable judgment, believes that the sharing of SERVICE INCOME
set forth in this subsection 4.1(f) on LICENSED SERVICES performed or provided by a SUBLICENSEE is economically infeasible in view
of its sublicense agreement with such SUBLICENSEE, COMPANY shall notify M.I.T., and the parties agree to discuss in good faith.
COMPANY and M.I.T. will enter into a written amendment to this Agreement with respect to any mutually agreed upon change(s) to
the SERVICE INCOME sharing obligation.

 

(g)          Milestone
Payments.

 

(i) COMPANY shall pay to M.I.T. the amounts
set forth below upon achievement by COMPANY or any of its AFFILIATES of certain milestone events as set forth below.

 

	THERAPEUTIC PRODUCT Milestones 	 	 
	Milestone
    Event	 	First

    THERAPEUTIC

    PRODUCT	 	Second

    THERAPEUTIC

    PRODUCT
	Enrollment of 1st individual in a PHASE 1 CLINICAL TRIAL	 	*	 	*
	Enrollment of 1st individual in a PHASE 2 CLINICAL TRIAL	 	*	 	*
	Enrollment of 1st individual in a PHASE 3 CLINICAL TRIAL	 	*	 	*
	Filing of submission/application for regulatory/marketing approval	 	*	 	*
	Receipt of regulatory/marketing approval	 	*	 	*

 

	DIAGNOSTIC PRODUCT Milestones 	 	 
	Milestone
    Event	 	First

    DIAGNOSTIC

    PRODUCT	 	Second

    DIAGNOSTIC

    PRODUCT
	First use in humans (including clinical testing)	 	*	 	*
	Receipt of Clinical Laboratory Improvement Amendments (CLIA) (or equivalent) certification	 	*	 	*
	Receipt of regulatory/marketing approval	 	*	 	*

 

    	24

    	 

    

 

	VETERINARY PRODUCT Milestones 	 	 
	Milestone
    Event	 	First

    VETERINARY

    PRODUCT	 	Second

    VETERINARY

    PRODUCT
	First use in non-human animals (including clinical testing)	 	*	 	*
	First commercial sale	 	*	 	*

 

COMPANY shall notify M.I.T. within ten
(10) days of the achievement of any of the above milestones by COMPANY or any of its AFFILIATES. COMPANY shall make such non-refundable,
non-creditable milestone payments within sixty (60) days after achievement of each of the milestones.

 

(ii) The milestone events set forth in Section
4.1(g)(i) above are intended to be successive. In the event that any PHASE 1 CLINICAL TRIAL is combined with a PHASE 2 CLINICAL
TRIAL (i.e., a PHASE 1/2 CLINICAL TRIAL), the milestone payment for the enrollment of the first patient in a PHASE 1 CLINICAL TRIAL
and the milestone payment for the enrollment of the first patient in a PHASE 2 CLINICAL TRIAL shall be due upon the enrollment
of the first patient in the PHASE 1/2 CLINICAL TRIAL; and in the event that any PHASE 2 CLINICAL TRIAL is combined with a PHASE
3 CLINICAL TRIAL (i.e., a PHASE 2/3 CLINICAL TRIAL), the milestone payment for the enrollment of the first patient in a PHASE 2
CLINICAL TRIAL and milestone payment for the enrollment of the first patient in a PHASE 3 CLINICAL TRIAL shall be due upon the
enrollment of the first patient in the PHASE 2/3 CLINICAL TRIAL. In addition and notwithstanding the foregoing, if any milestone
is reached without achieving a preceding milestone, then the amount which would have been payable on achievement of the preceding
milestone shall be payable upon achievement of the following milestone.

 

(iii) For the convenience of the parties,
in recognition of the value of the PATENT RIGHTS, LICENSED PRODUCTS and LICENSED PROCESSES in identifying DISCOVERED PRODUCTS,
and in the time it takes to develop DISCOVERED PRODUCTS, COMPANY agrees to pay milestones under this Section 4.1(g) on each DISCOVERED
PRODUCT identified and/or discovered during the TERM. The obligation to pay milestones on each DISCOVERED PRODUCT under this Section
4.1(g) shall survive termination of this agreement as specified in Section 12.6(a).

 

    	25

    	 

    

 

(h)          Sharing
of Consideration Related to DISCOVERED PRODUCTS. For the convenience of the parties, in recognition of the value of the PATENT
RIGHTS, LICENSED PRODUCTS and LICENSED PROCESSES in identifying DISCOVERED PRODUCTS, COMPANY agrees to share consideration received
by COMPANY and AFFILIATES related to DISCOVERED PRODUCTS with M.I.T. as described in this Article 4, including running royalties,
SUBLICENSE INCOME, CORPORATE PARTNER INCOME, SERVICE INCOME, and milestone payments. Unless otherwise expressly set forth in this
Article 4, the obligation to share consideration related to DISCOVERED PRODUCTS shall extend to the end of the TERM of this Agreement.

 

(i)          Consequences
of a PATENT CHALLENGE. In the event that (i) COMPANY or any of its AFFILIATES brings a PATENT CHALLENGE against M.I.T. (and/or
WHITEHEAD, HARVARD or HOSPITAL), or (ii) COMPANY or any of its AFFILIATES assists another party in bringing a PATENT CHALLENGE
against M.I.T. (and/or WHITEHEAD, HARVARD or HOSPITAL) (except as required under a court order or subpoena), and (iii) M.I.T. does
not choose to exercise its rights to terminate this Agreement pursuant to Section 12.4, then the running royalties due hereunder
with respect to the PATENTS being challenged shall be * for the remainder of the term of the Agreement. In the event that such
a PATENT CHALLENGE is successful, COMPANY will have no right to recoup any royalties paid during the period of challenge. In the
event that a PATENT CHALLENGE is unsuccessful, COMPANY shall reimburse M.I.T. (and/or WHITEHEAD, HARVARD or HOSPITAL) for all reasonable
legal fees and expenses incurred in its defense against the PATENT CHALLENGE.

 

(j)          No
Multiple Royalties. If the manufacture, use, lease, or sale of any LICENSED PRODUCT or the performance of any LICENSED PROCESS
is covered by more than one of the PATENT RIGHTS, multiple royalties shall not be due.

 

(k)          Equity.

 

(i)          Initial
Grant. COMPANY shall issue a total of Sixty-Six Thousand Three Hundred and Three (66,303) shares of Common Stock of COMPANY,
$.0001 par value per share, (the "Shares") to M.I.T. and those persons as M.I.T. shall direct ("M.I.T. Holder"),
WHITEHEAD, HARVARD and HOSPITAL, in the amounts as M.I.T. shall direct. Such issuance shall be recorded on the Stock Transfer Ledger
of COMPANY on the EFFECTIVE DATE and the Shares shall be delivered to M.I.T. and M.I.T. Holders, if any, within thirty (30) days
of the EFFECTIVE DATE.

 

    	26

    	 

    

 

COMPANY represents to M.I.T. that, as of
the EFFECTIVE DATE, the aggregate number of Shares equals Three Percent (3%) of the COMPANY's issued and outstanding Common Stock
calculated on a "Fully Diluted Basis." For purposes of this Section 4.1(k), "Fully Diluted Basis" shall mean
the total number of issued and outstanding shares of the COMPANY's Common Stock calculated to include conversion of all issued
and outstanding securities convertible into Common Stock, the exercise of all outstanding options and warrants to purchase shares
of Common Stock, whether or not then exercisable, and the conversion or exercise of all rights to purchase or acquire Common Stock,
whether or not then convertible or exercisable. Notwithstanding the foregoing, for purposes of calculating the COMPANY’s
issued and outstanding Fully Diluted Common Stock, all Convertible Notes issued prior to the close of the COMPANY’s initial
equity financing shall be excluded until the date of their conversion, at which time sufficient shares will be issued by COMPANY
to M.I.T., M.I.T. Holders, WHITEHEAD, HARVARD and HOSPITAL to maintain their aggregate ownership at Three Percent (3%) as described
in this Section.

 

(ii)         Anti-Dilution
Protection. COMPANY shall issue additional shares of Common Stock to M.I.T. WHITEHEAD, HARVARD, HOSPITAL and each M.I.T. Holder
pro rata, such that M.I.T.'s, WHITEHEAD’s, HARVARD’s, HOSPITAL’s and each M.I.T. Holders' ownership (collectively)
of outstanding Common Stock shall not fall below Three Percent (3%) on a Fully Diluted Basis, as calculated after giving effect
to the anti-dilutive issuance. Such issuances shall continue until and including the date upon which a total of Seven Million Five
Hundred Thousand Dollars ($7,500,000) in cash in exchange for COMPANY's capital stock (the "Funding Threshold") shall
be received by COMPANY. Thereafter, no additional shares shall be due to M.I.T., WHITEHEAD, HARVARD, HOSPITAL or any M.I.T. Holder
pursuant to this section.

 

(iii)        Participation
in Future Private Equity Offerings. After the date of the Funding Threshold, M.I.T. (specifically not including M.I.T. Holders),
WHITEHEAD, HARVARD and HOSPITAL shall have the right to purchase additional shares of COMPANY's capital stock in any private offering
by the COMPANY of such capital stock in exchange for cash (“OFFERING”), to maintain its pro rata ownership as calculated
immediately prior to such offering on a Fully Diluted Basis, pursuant to the terms and conditions at least as favorable as those
granted to the other offerees. All rights granted to M.I.T., WHITEHEAD, HARVARD and HOSPITAL pursuant to this Section 4.1(k)(iii)
shall terminate immediately (i) prior to a firm commitment underwritten public offering of the COMPANY's common stock resulting
in gross proceeds to the COMPANY of at least *. This right granted to M.I.T., WHITEHEAD, HARVARD and HOSPITAL shall not apply to
any equity issued to any lender, the issuance of any shares in connection with the conversion of any equity securities, the issuance
of securities to a collaboration partner or joint venture, or the issuance of any securities under any equity incentive plan.

 

    	27

    	 

    

 

(iv) Adjustments
for Punitive Round Financings. After the date of the Funding Threshold (the “Funding Threshold Date”), if COMPANY
takes any action that is a Dilutive Issuance (as defined below), then immediately following such Dilutive Issuance, COMPANY shall
issue to M.I.T., WHITEHEAD, HARVARD and HOSPITAL additional shares of Common Stock such that the Institution Share Number (as defined
below) equals the product obtained by multiplying the Institution Share Number in effect immediately before the Dilutive Issuance
by the Adjustment Fraction defined below. The Institution Share Price in effect immediately after the Dilutive Issuance shall be
adjusted to equal the result obtained by dividing the Institution Share Price in effect immediately before the Dilutive Issuance
by the Adjustment Fraction defined below.

	Adjust Fraction equals:	(A+C)
	 	(A+B)

 

Where:

 

A = the number of shares of Common Stock issued
and outstanding on a Fully Diluted Basis immediately prior to the Dilutive Issuance

 

B = the number of shares of Common Stock that
could be purchased at the Institution Share Price immediately prior to the Dilutive Issuance using the aggregate consideration
received by COMPANY in connection with the Dilutive Issuance.

 

For purposes of calculation of “B”,
if the Dilutive Issuance is as described in subpart (III) of the definition of Dilutive Issuance below, the aggregate consideration
received by COMPANY shall be the price per share of the applicable Convertible Instrument (as defined below) immediately following
the Dilutive Issuance (as adjusted for the Dilutive Issuance pursuant to the terms and conditions of the Convertible Instrument
or the COMPANY’s Certificate of Incorporation or other applicable formation document) multiplied by the total number of shares
of Capital Stock (as defined below) into which such newly adjusted Convertible Instrument could be exercised or converted, whether
or not then exercisable or convertible.

 

C = the number of shares of Capital Stock
issued on a Fully Diluted Basis pursuant to the Dilutive Issuance, or, if a Convertible Instrument is issued in the Dilutive Issuance,
the number of shares of Capital Stock issuable on a Fully Diluted Basis if all shares of the Convertible Instrument were converted
into the applicable Capital Stock, whether or not then exercisable or convertible.

 

For purposes of calculation of “C”,
if the Dilutive Issuance is as described in subpart (III) of the definition of Dilutive Issuance below, then C shall be the total
number of shares of Capital Stock into which the newly adjusted Convertible Instrument could be exercised or converted, whether
or not then exercisable or convertible.

 

    	28

    	 

    

 

The following definitions shall apply to this
Section 4.1(k)(iv):

 

“Capital Stock” shall mean any
form of COMPANY’s capital stock.

 

“Convertible Instrument” shall
mean any instrument issued by COMPANY that is convertible into, or may be exercised in exchange for, any Capital Stock.

 

“Dilutive Issuance” shall mean
any issuance of Capital Stock or any Convertible Instrument by COMPANY where such issuance results in (I) the price per share of
COMPANY’s Common Stock being reduced to less than the then current Institution Share Price (as defined in this subsection),
(II) the price per share of any Convertible Instrument being reduced to less than the price of the same series or type of Convertible
Instrument in the most recently preceding offering and sale of such Convertible Instrument, or (III) the conversion ratio of any
Convertible Instrument changing such that each previously issued shares of such Convertible Instrument becomes convertible into
a greater number of shares of the applicable Capital Stock.

 

“Institution Share Number” shall
mean the number of shares of COMPANY’s Common Stock that M.I.T., WHITEHEAD, HARVARD and HOSPITAL own on the date of the Dilutive
Issuance, as adjusted from time to time pursuant to this section. Notwithstanding the foregoing, any shares of Common Stock acquired
by M.I.T., WHITEHEAD, HARVARD or HOSPITAL pursuant to Section 4.1(k)(iii) shall not be included in the Institution Share Number.

 

“Institution Share Price” shall
mean the value per share of the shares of Common Stock included in the Institution Share Number, as adjusted from time to time
pursuant to this section. For purposes of this section, the initial Institution Share Price to be used in an adjustment resulting
from the first Dilutive Issuance to occur after the Funding Threshold Date shall be the Fair Market Value per share of the Common
Stock of the COMPANY effective on the Funding Threshold Date.

 

“Fair Market Value” of a share
of Common Stock shall be the highest price per share that the COMPANY could obtain from a willing buyer (not a current employee
or director) for shares of Common Stock sold by the COMPANY, from authorized but unissued shares, as determined in good faith by
the Board of Directors of the COMPANY, unless the COMPANY shall become subject to a merger, acquisition or other consolidation
pursuant to which the COMPANY is not the surviving party, in which case the current fair market value of a share of Common Stock
shall be deemed to be the value received by the holders of the COMPANY’s Common Stock for each share of Common Stock pursuant
to the COMPANY’s acquisition.

 

    	29

    	 

    

 

(v)  Massachusetts General Hospital.
If HOSPITAL’S ownership of HOSPITAL’S shares shall at any time create a conflict of interest affecting HOSPITAL’S
ability to conduct clinical trials, clinical studies, clinical research or clinical validation or if HOSPITAL shall otherwise be
required to divest itself of HOSPITAL’S shares due to law or HOSPITAL’S conflict of interest policies, then HOSPITAL
shall have the right to elect to sell (“TRANSFER”) the HOSPITAL’S shares to any third party (“PROPOSED
TRANSFEREE “) free of any restriction and free of any co-sale rights, tag along rights, of COMPANY or its stockholders
or investors provided however the HOSPITAL shall not transfer the HOSPITAL’s shares to a COMPETING ORGANIZATION or to an
investor in any COMPETING ORGANIZATION Such third party investor shall agree to execute any and all investment documents binding
on the HOSPITAL. Notwithstanding the foregoing, the COMPANY first and then the other stockholders of the Company shall have the
right of first refusal to purchase such shares at the price offered to such third party by the Hospital pursuant to the following
conditions. HOSPITAL shall first offer to sell to the COMPANY or any Persons designated by the Company
as the “Purchaser” hereunder (the Company or such designees being referred to as the “DESIGNATED PURCHASER”)
the HOSPITAL’S shares that the HOSPITAL desires to sell (the “OFFERED SECURITIES”),
at the same price and on the terms identical in all material respects to those terms that the HOSPITAL intends to sell the OFFERED
SECURITIES to the PROPOSED TRANSFEREE; provided that the DESIGNATED PURCHASER shall have no right to acquire the OFFERED
SECURITIES unless the DESIGNATED PURCHASER acquires all of the OFFERED SECURITIES. If such proposed TRANSFER involves consideration
other than cash, any Person having rights under this subparagraph (v) shall have the right to elect to pay, in lieu of such non-cash
consideration, cash in an amount equal to the fair market value of such non-cash consideration. Such offer shall be made by a written
notice (the “NOTICE of PROPOSED TRANSFER”) delivered to the COMPANY not less than thirty (30) days prior to the PROPOSED
TRANSFER. Such NOTICE of PROPOSED TRANSFER shall set forth the identity of the PROPOSED TRANSFEREE, the OFFERED SECURITIES proposed
to be sold, the terms and conditions of the proposed sale, including price per share and any other material terms and conditions
or material facts relating to the proposed sale. In addition, the HOSPITAL shall provide to the DESIGNATED PURCHASER all such other
information relating to the OFFERED SECURITIES, the PROPOSED TRANSFEREE and the proposed sale as the DESIGNATED PURCHASER may reasonably
request. If the DESIGNATED PURCHASER does not accept the HOSPITAL’S offer with respect to all of the OFFERED SECURITIES within
fifteen (15) days after receipt of the NOTICE of PROPOSED TRANSFER from HOSPITAL, the HOSPITAL shall have the right for a period
of sixty (60) days following the sixtieth day after the COMPANY received the NOTICE of PROPOSED TRANSFER from the HOSPITAL, to
sell all of the OFFERED SECURITIES, but at not less than the price, and upon terms not more favorable to the PROPOSED TRANSFEREE,
than were contained in the NOTICE OF PROPOSED TRANSFER. If the OFFERED SECURITIES are not sold within such 60-day period, such
OFFERED SECURITIES shall continue to be subject to the requirements of this subparagraph (v).

 

4.2 Payments.

 

(a)          
Method of Payment. All payments under this Agreement should be made payable to "Massachusetts Institute of Technology"
and sent to the address identified in Section 14.1. Each payment should reference this Agreement and identify the obligation
under this Agreement that the payment satisfies. Notwithstanding the foregoing, any payments due to HARVARD under Section 6.3 of
this Agreement should be paid in accordance with HARVARD’s instructions.

 

(b)          Payments in U.S. Dollars. All
payments due under this Agreement shall be drawn on a United States bank and shall be payable in United States dollars. Conversion
of foreign currency to U.S. dollars shall be made at the conversion rate existing in the United States (as reported in by the Federal
Reserve Bank of St. Louis) on the last working day of the calendar quarter of the applicable REPORTING PERIOD. Such payments shall
be without deduction of exchange, collection, or other charges, and, specifically, without deduction of withholding or similar
taxes or other government imposed fees or taxes, except as permitted in the definition of NET SALES.

 

    	30

    	 

    

 

(c)          Late Payments. Any payments
by COMPANY that are not paid on or before the date such payments are due under this Agreement shall bear interest, to the extent
permitted by law, at two percentage points above the Prime Rate of interest as reported by the Federal Reserve Bank of St. Louis
on the date payment is due.

 

5. REPORTS
AND RECORDS.

 

5.1 Frequency of Reports.

 

(a)          Before
First Commercial Sale. Prior to the first commercial sale of any LICENSED PRODUCT or DISCOVERED PRODUCT or first commercial
performance of any LICENSED PROCESS, or first agreement with a CORPORATE PARTNER, COMPANY shall deliver reports to M.I.T. annually,
within sixty (60) days of the end of each calendar year, containing information concerning the immediately preceding calendar year,
as further described in Section 5.2.

 

(b)          Upon
First Commercial Sale of a LICENSED PRODUCT or DISCOVERED PRODUCT or Commercial Performance of a LICENSED PROCESS. COMPANY
shall report to M.I.T. the date of first commercial sale of a LICENSED PRODUCT or DISCOVERED PRODUCT and the date of first commercial
performance of a LICENSED PROCESS, or first agreement with a CORPORATE PARTNER, within sixty (60) days of occurrence in each country.

 

(c)          After
First Commercial Sale. After the first commercial sale of a LICENSED PRODUCT or DISCOVERED PRODUCT or first commercial performance
of a LICENSED PROCESS, or first agreement with a CORPORATE PARTNER, COMPANY shall deliver reports to M.I.T. within sixty (60) days
of the end of each REPORTING PERIOD, containing information concerning the immediately preceding REPORTING PERIOD, as further described
in Section 5.2.

 

5.2 Content of Reports and Payments.
Each report delivered by COMPANY to M.I.T. shall contain at least the following information for the immediately preceding REPORTING
PERIOD:

 

(i) the number of LICENSED PRODUCTS and DISCOVERED
PRODUCTS sold, leased or distributed by COMPANY, its AFFILIATES, SUBLICENSEES and, if applicable, CORPORATE PARTNERS to independent
third parties in each country, and, if applicable, the number of LICENSED PRODUCTS and DISCOVERED PRODUCTS used by COMPANY, its
AFFILIATES, SUBLICENSEES in the provision of services in each country;

 

    	31

    	 

    

 

(ii) a description of LICENSED PROCESSES or
LICENSED SERVICES performed by COMPANY, its AFFILIATES and SUBLICENSEES in each country as may be pertinent to a royalty accounting
hereunder;

 

(iii) the gross price charged by COMPANY,
its AFFILIATES, SUBLICENSEES and, if applicable, CORPORATE PARTNERS for each LICENSED PRODUCT and DISCOVERED PRODUCT and, if applicable,
the gross price charged for each LICENSED PRODUCT and DISCOVERED PRODUCT used to provide services in each country; and the gross
price charged for each LICENSED PROCESS and LICENSED SERVICE performed by COMPANY, its AFFILIATES and SUBLICENSEES in each country;

 

(iv) calculation of NET SALES for the applicable
REPORTING PERIOD in each country, including a listing of applicable deductions;

 

(v) total royalty payable on NET SALES in
U.S. dollars, together with the exchange rates used for conversion;

 

(vi) calculation of SERVICE INCOME for the
applicable REPORTING PERIOD in each country, and the amount due to M.I.T. from such SERVICE INCOME in U.S. dollars, together with
the exchange rates used for conversion; and

 

(vii) the amount of SUBLICENSE INCOME received
by COMPANY and its AFFILIATES from each SUBLICENSEE and the amount due to M.I.T. from such SUBLICENSE INCOME, including an itemized
breakdown of the sources of income comprising the SUBLICENSE INCOME; and

 

(viii) the number of sublicenses entered into
for the PATENT RIGHTS, LICENSED PRODUCTS and/or LICENSED PROCESSES; and

 

(ix) the amount of CORPORATE PARTNER INCOME
received by COMPANY, its AFFILIATES and SUBLICENSEES from each CORPORATE PARTNER and the amount due to M.I.T. from such CORPORATE
PARTNER INCOME, including an itemized breakdown of the sources of income comprising the CORPORATE PARTNER INCOME; and

 

    	32

    	 

    

 

(x) the number of agreements entered into
with CORPORATE PARTNERS and a fully signed photocopy of any such CORPORATE PARTNER agreements.

 

If no amounts are due to M.I.T. for any
REPORTING PERIOD, the report shall so state.

 

Notwithstanding the foregoing, if the discovery,
development, use or sale of a DISCOVERED PRODUCT by a CORPORATE PARTNER or SUBLICENSEE is unknown to COMPANY or an AFFILIATE and
does not result in any payments to COMPANY or an AFFILIATE, then the reporting requirements under this Section 5.2 with respect
to such DISCOVERED PRODUCT shall be waived.

 

5.3 Financial Statements. On or before
the ninetieth (90th) day following the close of COMPANY's fiscal year, COMPANY shall provide M.I.T. with COMPANY's financial statements
for the preceding fiscal year including, at a minimum, a balance sheet and an income statement, certified by COMPANY's treasurer
or chief financial officer or by an independent auditor.

 

5.4 Records. COMPANY shall maintain,
and shall cause its AFFILIATES and SUBLICENSEES and CORPORATE PARTNERS to maintain, complete and accurate records relating to the
rights and obligations under this Agreement and any amounts payable to M.I.T. in relation to this Agreement, which records shall
contain sufficient information to permit M.I.T. to confirm the accuracy of any reports delivered to M.I.T. and compliance in other
respects with this Agreement. The relevant party shall retain such records for at least five (5) years following the end of the
calendar year to which they pertain, during which time M.I.T., or M.I.T.'s appointed independent third party accountants , shall
have the right, at M.I.T.'s expense, to inspect such records during normal business hours to verify any reports and payments made
or compliance in other respects under this Agreement. In the event that any audit performed under this Section reveals an underpayment
in excess of *, COMPANY shall bear the full cost of such audit and shall remit any amounts due to M.I.T. within thirty (30) days
of receiving notice thereof from M.I.T.

 

5.5 Confidential Information.

 

(a) Designation. CONFIDENTIAL
INFORMATION that is disclosed in writing shall be marked with a legend indicating its confidential status (such as “Confidential”
or “Proprietary”). CONFIDENTIAL INFORMATION that is disclosed orally or visually shall be documented in a written notice
prepared by a Disclosing Party and delivered to the Receiving Party within thirty (30) days of the date of disclosure; such notice
shall summarize the CONFIDENTIAL INFORMATION disclosed to the Receiving Party and reference the time and place of disclosure.

 

    	33

    	 

    

 

(b) Obligations. For a period
of five (5) years after disclosure of any portion of CONFIDENTIAL INFORMATION, the Receiving Party shall (i) maintain such CONFIDENTIAL
INFORMATION in strict confidence, except that the Receiving Party may disclose or permit the disclosure of any CONFIDENTIAL INFORMATION
to its directors, officers, employees, consultants, and advisors who are obligated to maintain the confidential nature of such
CONFIDENTIAL INFORMATION and who need to know such CONFIDENTIAL INFORMATION for the purposes of this Agreement; (ii) use such CONFIDENTIAL
INFORMATION solely for the purposes of this Agreement; and (iii) allow its trustees or directors, officers, employees, consultants,
and advisors to reproduce the CONFIDENTIAL INFORMATION only to the extent necessary for the purposes of this Agreement, with all
such reproductions being considered CONFIDENTIAL INFORMATION.

 

(c) Exceptions. The obligations
of the Receiving Party under Subsection 7.1(b) above shall not apply to the extent that the Receiving Party can demonstrate that
certain CONFIDENTIAL INFORMATION (i) was in the public domain prior to the time of its disclosure under this Agreement; (ii) entered
the public domain after the time of its disclosure under this Agreement through means other than an authorized disclosure resulting
from an act or omission by the Receiving Party; (iii) was independently developed or discovered by the Receiving Party without
use of the CONFIDENTIAL INFORMATION; (iv) is or was disclosed to the Receiving Party at any time, whether prior to or after the
time of its disclosure under this Agreement, by a third party having no fiduciary relationship with the Disclosing Party and having
no obligation of confidentiality with respect to such CONFIDENTIAL INFORMATION ; or (v) is required to be disclosed to comply with
applicable laws or regulations, or with a court or administrative order, provided that the Disclosing Party receives reasonable
prior written notice of such disclosure.

 

(d) Ownership and Return. The
Receiving Party acknowledges that the Disclosing Party (or any third party entrusting its own information to the Disclosing Party)
claims ownership of its CONFIDENTIAL INFORMATION in the possession of the Receiving Party. Upon the expiration or termination of
this Agreement, and at the request of the Disclosing Party, the Receiving Party shall return to the Disclosing Party all originals,
copies, and summaries of documents, materials, and other tangible manifestations of CONFIDENTIAL INFORMATION in the possession
or control of the Receiving Party, except that the Receiving Party may retain one copy of the CONFIDENTIAL INFORMATION in the possession
of its legal counsel solely for the purpose of monitoring its obligations under this Agreement.

 

    	34

    	 

    

 

6. PATENT
PROSECUTION.

 

6.1 Responsibility for PATENT RIGHTS.
M.I.T. shall prepare, file, prosecute, and maintain all of the PATENT RIGHTS, but excluding the HARVARD PATENT RIGHTS (for which
HARVARD shall retain such responsibility), using patent counsel reasonably acceptable to COMPANY, such acceptance not to be unreasonably
withheld. COMPANY shall have reasonable opportunities to advise M.I.T. and shall cooperate with M.I.T. in such filing, prosecution
and maintenance. M.I.T. shall instruct its patent counsel to copy COMPANY on all patent prosecution documents relating to
the PATENT RIGHTS, but excluding the HARVARD PATENT RIGHTS. In addition, M.I.T. shall request that HARVARD instruct its patent
counsel to copy COMPANY on all patent prosecution documents relating to the HARVARD PATENT RIGHTS and to consult with COMPANY
on patent prosecution decisions with respect thereto. In the event that COMPANY disputes any bill issued by such patent counsel,
M.I.T. will reasonably cooperate with patent counsel and COMPANY in seeking to resolve the dispute.

 

6.2 International (non-United States)
Filings. Appendix B is a list of countries in which patent applications corresponding to the United States patent applications
listed in Appendix A shall be filed, prosecuted, and maintained. Appendix B may be amended by mutual agreement of
COMPANY and M.I.T.

 

6.3 Payment of Expenses. Payment
of all fees and costs, including attorneys’ fees, relating to the filing, prosecution and maintenance of the PATENT RIGHTS
shall be the responsibility of COMPANY, whether such amounts were incurred before or after the EFFECTIVE DATE. As of March 19,
2011, M.I.T. has incurred approximately * for such patent-related fees and costs. In addition, as of _____________, Harvard has
incurred approximately $__________ for such patent-related fees and costs related to the HARVARD PATENT RIGHTS.

 

(a)          Payment
of Patent Costs Incurred Before the EFFECTIVE DATE. COMPANY shall reimburse M.I.T. and Harvard, respectively, for all of their
actual expenses incurred as of the EFFECTIVE DATE in connection with the preparation, filing, prosecution and maintenance of the
PATENT RIGHTS (“PRE-EFFECTIVE DATE COSTS”) as follows. COMPANY shall reimburse M.I.T. for the PRE-EFFECTIVE DATE COSTS
in three equal installments. The first installment shall be due on the EFFECTIVE DATE; the second installment shall be due on the
first anniversary of the EFFECTIVE DATE; and the third installment shall be due on the second anniversary of the EFFECTIVE DATE.
Notwithstanding the foregoing, all installments shall be immediately due to M.I.T. at the time of COMPANY having raised funds of
at least * from any source. COMPANY shall reimburse Harvard for all of the PRE-EFFECTIVE DATE COSTS for the HARVARD PATENT RIGHTS
on the EFFECTIVE DATE.

 

    	35

    	 

    

 

(b)          Payment
of Patent Costs Incurred After the EFFECTIVE DATE. As of the EFFECTIVE DATE, payment of all fees and costs, including attorneys’
fees, relating to the filing, prosecution and maintenance of the PATENT RIGHTS shall be the responsibility of COMPANY.

 

COMPANY shall reimburse all amounts due
pursuant to this Section 6.3 within thirty (30) days of invoicing; late payments shall accrue interest pursuant to Section 4.2(c).
For clarity, upon invoicing from HARVARD, COMPANY shall reimburse HARVARD directly for amounts due with respect to the HARVARD
PATENT RIGHTS. In all instances if required, M.I.T. and HARVARD shall pay the fees prescribed for large entities to the United
States Patent and Trademark Office.

 

7. INFRINGEMENT.

 

7.1 Notification of Infringement.
Each party agrees to provide written notice to the other party promptly after becoming aware of any infringement of the PATENT
RIGHTS.

 

7.2 Right to Prosecute Infringements.

 

(a)          COMPANY
Right to Prosecute. So long as COMPANY remains the exclusive licensee of the PATENT RIGHTS in the FIELD in the TERRITORY, COMPANY,
to the extent permitted by law, shall have the right, under its own control and at its own expense, to prosecute any third party
infringement of the PATENT RIGHTS in the FIELD in the TERRITORY, subject to Sections 7.4 and 7.5. M.I.T., WHITEHEAD, HARVARD
and HOSPITAL shall permit any action under this Section to be brought in its name, including being joined as a party-plaintiff,
provided that COMPANY shall hold M.I.T., WHITEHEAD, HARVARD and HOSPITAL harmless from, and indemnify M.I.T., WHITEHEAD, HARVARD
and HOSPITAL against, any costs, expenses, or liability that M.I.T., WHITEHEAD, HARVARD or HOSPITAL incurs in connection with such
action.

 

    	36

    	 

    

 

Prior to commencing any such action, COMPANY
shall consult with M.I.T. (and HARVARD with respect to the HARVARD PATENT RIGHTS) and shall consider the views of M.I.T. (and HARVARD
with respect to the HARVARD PATENT RIGHTS) regarding the advisability of the proposed action and its effect on the public interest.
COMPANY shall not enter into any settlement, consent judgment, or other voluntary final disposition of any infringement action
under this Section without the prior written consent of M.I.T. (subject to concurrence of WHITEHEAD, HARVARD and/or HOSPITAL, as
applicable).

 

(b)          M.I.T.
Right to Prosecute. In the event that COMPANY is unsuccessful in persuading the alleged infringer to desist or entering into
a settlement agreement with such alleged infringer or fails to have initiated an infringement action within a reasonable time after
COMPANY first becomes aware of the basis for such action (which period shall be at least * days), M.I.T. shall have the right,
at its sole discretion, to prosecute such infringement under its sole control and at its sole expense, and any recovery obtained
shall belong to M.I.T.

 

7.3 Declaratory Judgment Actions.
In the event that a PATENT CHALLENGE is brought against M.I.T. or COMPANY by a third party, the COMPANY, at its option, shall have
the right within * days after commencement of such action to take over the sole defense of the action at its own expense, subject
to Sections 7.4 and 7.5. If COMPANY does not exercise this right, M.I.T. may take over the sole defense of the action at M.I.T.’s
sole expense if such action relates to PATENT RIGHTS other than the HARVARD PATENT RIGHTS, and HARVARD may take over the sole defense
of the action at HARVARD’s sole expense if such action relates solely to the HARVARD PATENT RIGHTS.

 

7.4 Offsets. COMPANY may offset a
total of * of any expenses incurred under Sections 7.2 and 7.3 against any payments due to M.I.T. under Article 4, provided that
in no event shall such payments under Article 4, when aggregated with any other offsets and credits allowed under this Agreement,
be reduced by more than * in any REPORTING PERIOD.

 

7.5 Recovery. Any recovery obtained
in an action brought by COMPANY under Sections 7.2 or 7.3 shall be distributed as follows: (i) each party shall be reimbursed
for any expenses incurred in the action (including the amount of any royalty or other payments withheld from M.I.T. as described
in Section 7.4, (ii) as to ordinary damages, COMPANY shall receive an amount equal to its lost profits or a reasonable royalty
on the infringing sales, or whichever measure of damages the court shall have applied, and COMPANY shall pay to M.I.T. based upon
such amount a reasonable approximation of the royalties and other amounts that COMPANY would have paid to M.I.T. if COMPANY had
sold the infringing products, processes and services rather than the infringer, and (iii) as to special or punitive damages, the
parties shall share equally in any award.

 

    	37

    	 

    

 

7.6 Cooperation. Each party agrees
to cooperate in any action under this Article which is controlled by the other party, provided that the controlling party reimburses
the cooperating party promptly for any costs and expenses incurred by the cooperating party in connection with providing such assistance.

 

7.7 Right to Sublicense. So long
as COMPANY remains the exclusive licensee of the PATENT RIGHTS in the FIELD in the TERRITORY, COMPANY shall have the sole right
to sublicense any alleged infringer in the FIELD in the TERRITORY for future use of the PATENT RIGHTS in accordance with the terms
and conditions of this Agreement relating to sublicenses. Any upfront fees as part of such sublicense shall be shared equally between
COMPANY and M.I.T.; other revenues to COMPANY pursuant to such sublicense shall be treated as set forth in Article 4.

 

    	38

    	 

    

 

8. INDEMNIFICATION
AND INSURANCE

 

8.1 Indemnification.

 

(a)          Indemnity. COMPANY shall indemnify,
defend, and hold harmless M.I.T., Whitehead, Harvard and Hospital (collectively, the “Institutions”), the affiliates
of the Institutions, and the respective directors, trustees, officers, faculty, students, employees, and agents and the respective
successors, heirs and assigns of any of the foregoing (the "Indemnitees"), against any third party liability, damage,
loss, or expense (including reasonable attorneys’ fees and expenses) incurred by or imposed upon any of the Indemnitees in
connection with any claims, suits, investigations, actions, demands or judgments arising out of (i) any theory of product liability
(including without limitation actions in the form of tort, warranty, or strict liability and regardless of whether such action
has any factual basis) concerning any product, process, or service that is made, used, sold, imported, or performed pursuant to
any right or license granted under this Agreement, or (ii) arising out of or related to the exercise of any rights granted to COMPANY
under this Agreement or any breach of this Agreement by COMPANY. Notwithstanding the foregoing, the COMPANY shall have no obligation
to indemnify any Indemnitee for any liability, damage, loss, or expense (including reasonable attorneys’ fees and expenses)
arising out of or in connection with, in whole or in part, the gross negligence or willful misconduct of any Indemnitee.

 

HHMI and its trustees, officers, employees,
and agents (collectively, “HHMI Indemnitees”), will be indemnified, defended by counsel acceptable to HHMI, and held
harmless by COMPANY from and against any claim, liability, cost, expense, damage, deficiency, loss, or obligation, of any kind
or nature (including, without limitation, reasonable attorneys’ fees and other costs and expenses of defense) (collectively,
“Claims”), based upon, arising out of, or otherwise relating to this Agreement, including without limitation any cause
of action relating to product liability. The previous sentence will not apply to the extent that a Claim is determined with finality
by a court of competent jurisdiction to result solely form the gross negligence or willful misconduct of an HHMI Indemnitee.

 

    	39

    	 

    

 

(b) Procedures. The Indemnitees
agree to provide COMPANY with prompt written notice of any claim, suit, action, demand, or judgment for which indemnification is
sought under this Agreement. COMPANY agrees, at its own expense, to provide attorneys reasonably acceptable to M.I.T. to defend
against any such claim, whether or not such claims are rightfully brought. The Indemnitees shall extend reasonable cooperation
to COMPANY in such defense and will permit COMPANY to conduct and control such defense and the disposition of such claim, suit,
or action (including all decisions relative to litigation, appeal, and settlement); provided, however, that any Indemnitee shall
have the right to retain its own counsel, at the expense of COMPANY, if representation of such Indemnitee by the counsel retained
by COMPANY would be inappropriate because of actual or potential differences in the interests of such Indemnitee and any other
party represented by such counsel. COMPANY agrees to keep M.I.T., WHITEHEAD, HARVARD and HOSPITAL (as applicable) informed of the
progress in the defense and disposition of such claim and to consult with M.I.T., WHITEHEAD, HARVARD and HOSPITAL (as applicable)
with regard to any proposed settlement.

 

Notwithstanding anything to the contrary in
this Agreement, COMPANY shall not enter into any settlement, consent judgment, or other voluntary final disposition of any claim
that has a material adverse effect on the rights of any Indemnitee(s) hereunder or admits any wrongdoing or fault by any Indemnitee(s)
or imposes on any Indemnitee(s) any payment or other liability, without the prior written consent of such Indemnitee(s).

 

In the case of HHMI Indemnitee, notice shall
be given reasonably promptly following actual receipt of written notice thereof by an officer or attorney of HHMI. Notwithstanding
the foregoing, the delay or failure of any HHMI Indemnitee to give reasonably prompt notice to COMPANY of any such claim shall
not affect the rights of such HHMI Indemnitee, unless, and then only to the extent that such a delay or failure is prejudicial
to or otherwise adversely affects COMPANY. COMPANY shall not settle any Claims against any HHMI Indemnitee without HHMI’s
written consent, where (a) such settlement would include an admission of liability on the part of any HHMI Indemnitee, (b) such
settlement would impose any restrictions on any HHMI Indemnitee’s conduct of any of its activities, or (c) such settlement
would not include an unconditional release of all HHMI Indemnitees from all liability for claims that are the subject matter of
the settled Claim. COMPANY agrees, at its own expense, to provide attorneys to defend against any such Claim, to keep HHMI informed
of the progress in the defense and disposition of any such Claim, and to consult with HHMI with regard to any proposed settlement.

 

    	40

    	 

    

 

8.2 Insurance. Commencing at the
earlier of (1) the six (6) month anniversary of the EFFECTIVE DATE, or (2) the date upon which COMPANY or an AFFILIATE, SUBLICENSEE
or CORPORATE PARTNER commences research and development activities related to and/or using LICENSED PRODUCTS or LICENSED PROCESSES
(including without limitation any distribution, sale, lease, transfer, performance or use of LICENSED PRODUCTS or LICENSED PROCESSES)
COMPANY shall, at its sole cost and expense, obtain and carry in full force and effect commercial general liability insurance,
including product liability insurance (subject to clause (iii) below) and errors and omissions insurance which shall protect COMPANY,
Indemnitees and HHMI Indemnitees with respect to events covered by Section 8.1(a) above. Such insurance (i) shall be issued
by an insurer licensed to practice in the Commonwealth of Massachusetts or an insurer pre-approved by M.I.T., such approval not
to be unreasonably withheld, (ii) shall list M.I.T., Whitehead, Harvard and Hospital as additional insureds thereunder, (iii) shall
include product liability coverage and broad form contractual liability coverage, and (iv) shall require thirty (30) days written
notice to be given to M.I.T. prior to any cancellation, non-renewal, or material change thereof. The limits of such insurance shall
not be less than Two Million Dollars ($2,000,000) per occurrence with an aggregate of Three Million Dollars ($3,000,000) for bodily
injury including death; Two Million Dollars ($2,000,000) per occurrence with an aggregate of Three Million Dollars ($3,000,000)
for property damage; and Two Million Dollars ($2,000,000) per occurrence with an aggregate of Three Million Dollars ($3,000,000)
for errors and omissions. In the alternative, COMPANY may self-insure subject to prior approval of M.I.T., Hospital and the Risk
Management Foundation. The minimum amounts of insurance coverage required under this Section 8.2 shall not be construed to create
a limit of COMPANY’s liability with respect to its indemnification under Section 8.1 of this Agreement.  COMPANY shall
provide M.I.T. with Certificates of Insurance evidencing compliance with this Section. COMPANY shall continue to maintain such
insurance or self-insurance after the expiration or termination of this Agreement during any period in which COMPANY or any AFFILIATE
or SUBLICENSEE or CORPORATE continues (i) to make, use, or sell a product that was a LICENSED PRODUCT under this Agreement or (ii)
to perform a service that was a LICENSED PROCESS under this Agreement, and thereafter for a period of five (5) years.

 

If there is a cancellation, non-renewal,
or material change in insurance, and COMPANY does not obtain replacement insurance providing comparable coverage prior to the expiration
of the thirty (30) day notice period described above, M.I.T. shall have the right to terminate this Agreement effective at the
end of such thirty (30) day period. For clarity, this termination clause applies to any material changes in the following terms:
(i) commercial general liability insurance in amounts not less than $2,000,000 per incident and $3,000,000 annual aggregate; (ii)
the naming of Indemnitees as additional insureds; and (iii) product liability coverage and broad form contractual liability coverage
for the company's indemnification under Section 8.1 of this Agreement.

 

    	41

    	 

    

 

9. NO REPRESENTATIONS
OR WARRANTIES

 

EXCEPT AS OTHERWISE EXPRESSLY SET FORTH
IN THIS AGREEMENT, M.I.T., WHITEHEAD, HARVARD AND HOSPITAL MAKE NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE PATENT
RIGHTS AND THE RIGHTS GRANTED HEREUNDER, AND HEREBY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING
WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS
OF M.I.T., WHITEHEAD, HARVARD OR HOSPITAL OR THIRD PARTIES, VALIDITY, ENFORCEABILITY AND SCOPE OF PATENT RIGHTS, WHETHER ISSUED
OR PENDING, AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE.

 

IN NO EVENT SHALL M.I.T., WHITEHEAD, HARVARD,
HOSPITAL, THEIR TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY
KIND, INCLUDING ECONOMIC DAMAGES OR INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS OF WHETHER M.I.T. SHALL BE ADVISED, SHALL HAVE
OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING.

 

10. ASSIGNMENT.

 

This Agreement may not be assigned by COMPANY
without the prior written consent of M.I.T. Notwithstanding the foregoing, COMPANY may, without the prior written consent of M.I.T.,
assign its rights and obligations under this Agreement to an AFFILIATE or to a successor in connection with the transfer of merger,
consolidation, or sale of all or substantially all of its assets or that portion of its business to which this Agreement relates;
provided, however, that:

 

(i) COMPANY shall deliver written notice
to M.I.T. at least fifteen (15) business days prior to the consummation of any such proposed assignment, such notice to include
the assignee’s contact information;

 

(ii) this Agreement shall immediately terminate
if the proposed assignee fails to agree in writing to M.I.T. to be bound by the terms and conditions of this Agreement on or before
the effective date of such assignment, such notice to M.I.T. to also include the proposed assignee’s express agreement to
either clause (a) or (b) below:

 

(a) to continue to develop and make
LICENSED PRODUCTS and LICENSED PROCESSES reasonably available to the biotechnology and pharmaceutical market for research, discovery
and/or development of diagnostic, biological and/or pharmaceutical products in accordance with the diligence provisions set forth
in Appendix D. For clarify, upon assignment of this Agreement, the assignee shall be bound by the diligence provisions set
forth in Appendix D; or

 

    	42

    	 

    

 

(b) the EXCLUSIVE PERIOD shall terminate
as of the effective date of the assignment, and the license granted hereunder shall become nonexclusive.

 

(iii) COMPANY (or any AFFILIATES) is not
in default of any obligation under this Agreement (including without limitation payment of any amounts due under this Agreement
and/or diligence obligations) at the time of such proposed assignment.

 

Notwithstanding and in addition to the foregoing,
if COMPANY assigns its rights and obligations under this Agreement at any time prior to fulfilling the obligations of Section 3.1(i),
(k), (l) and (p), then COMPANY shall pay to M.I.T. an Assignment Fee of *, due on the effective date of such assignment

 

Any attempted assignment in violation of
this Article 10 is void.

 

11. GENERAL
COMPLIANCE WITH LAWS

 

11.1 Compliance with Laws. COMPANY
shall use reasonable commercial efforts to comply with all commercially material local, state, federal, and international laws
and regulations relating to the development, manufacture, use, and sale of LICENSED PRODUCTS and LICENSED PROCESSES.

 

11.2 Export Control. COMPANY and
its AFFILIATES and SUBLICENSEES shall comply with all United States laws and regulations controlling the export of certain commodities
and technical data, including without limitation all Export Administration Regulations of the United States Department of Commerce.
Among other things, these laws and regulations prohibit or require a license for the export of certain types of commodities and
technical data to specified countries. COMPANY hereby gives written assurance that it will comply with, and will cause its AFFILIATES
and SUBLICENSEES to comply with, all United States export control laws and regulations, that it bears sole responsibility for any
violation of such laws and regulations by itself or its AFFILIATES or SUBLICENSEES, and that it will indemnify, defend, and hold
M.I.T., Whitehead, Harvard, Hospital and HHMI harmless (in accordance with Section 8.1) for the consequences of any such violation.

 

    	43

    	 

    

 

11.3 Non-Use of Name.

 

(a) COMPANY and its AFFILIATES and SUBLICENSEES
and CORPORATE PARTNERS shall not use the name of "Massachusetts Institute of Technology," "Lincoln Laboratory",
the Whitehead Institute for Biomedical Research”, “Harvard University”, “Massachusetts General Hospital”
or any variation, adaptation, or abbreviation thereof, or of any of its trustees, directors, officers, faculty, students, employees,
or agents, or any trademark owned by M.I.T., Whitehead, Harvard or Hospital, or any terms of this Agreement in any advertising,
promotional or sales material or other public announcement or disclosure, including any document employed to obtain funds or financing,
without the prior written consent of the applicable party, which consent any party may withhold in its sole discretion. For Hospital,
such approval shall be obtained from Hospital’s Chief Public Affairs Officer. The foregoing notwithstanding, without the
consent of M.I.T., Whitehead, Harvard or Hospital, COMPANY may make factual statements during the term of this Agreement that COMPANY
has a license from M.I.T. under one or more of the patents and/or patent applications comprising the PATENT RIGHTS.

 

(b) COMPANY acknowledges that under
HHMI policy, none of COMPANY, AFFILIATES or SUBLICENSEES may use the name of HHMI or of any HHMI employee (including *) in a manner
that reasonably could constitute an endorsement of a commercial product or service; but that use for other purposes, even if commercially
motivated, is permitted provided that (1) the use is limited to accurately reporting factual events or occurrences, and (2) any
reference to the name of HHMI or any HHMI employee (including *) in press releases or similar materials intended for public release
is approved by HHMI in advance.

 

11.4 Marking of LICENSED PRODUCTS.
To the extent commercially feasible and consistent with prevailing business practices, COMPANY shall mark, and shall cause its
AFFILIATES and SUBLICENSEES to mark, all LICENSED PRODUCTS that are manufactured or sold under this Agreement with the number of
each issued patent under the PATENT RIGHTS that applies to such LICENSED PRODUCT.

 

12. TERMINATION

 

12.1 Voluntary Termination by COMPANY.
COMPANY shall have the right to terminate this Agreement, for any reason, (i) upon at least three (3) months prior written notice
to M.I.T., such notice to state the date at least three (3) months in the future upon which termination is to be effective, and
(ii) upon payment of all amounts due to M.I.T. through such termination effective date.

 

    	44

    	 

    

 

12.2 Cessation of Business. If COMPANY
ceases to carry on its business related to this Agreement, M.I.T. shall have the right to terminate this Agreement immediately
upon written notice to COMPANY.

 

12.3 Termination for Default.

 

(a)          Nonpayment.
In the event COMPANY fails to pay any amounts due and payable to M.I.T. hereunder, and fails to make such payments within thirty
(30) days after receiving written notice of such failure, M.I.T. may terminate this Agreement immediately upon written notice to
COMPANY.

 

(b)          Material
Breach. In the event COMPANY commits a material breach of its obligations under this Agreement, except for breach as described
in Section 12.3(a), and fails to cure that breach within ninety (90) days after receiving written notice thereof, M.I.T. may terminate
this Agreement immediately upon written notice to COMPANY.

 

12.4 Termination as a Consequence of
PATENT CHALLENGE.

 

(a)          By
COMPANY. If COMPANY or any of its AFFILIATES brings a PATENT CHALLENGE against M.I.T., (and/or WHITEHEAD, HARVARD or HOSPITAL)
or assists others in bringing a PATENT CHALLENGE against M.I.T. (and/or WHITEHEAD, HARVARD or HOSPITAL) (except as required under
a court order or subpoena), then M.I.T. may immediately terminate this Agreement.

 

(b)          By
SUBLICENSEE. If a SUBLICENSEE brings a PATENT CHALLENGE or assists another party in bringing a PATENT CHALLENGE against M.I.T.,
WHITEHEAD, HARVARD and/or HOSPITAL (except as required under a court order or subpoena), then M.I.T. may send a written demand
to COMPANY to terminate such sublicense. If COMPANY fails to so terminate such sublicense within thirty (30) days after M.I.T.’s
demand, M.I.T. may immediately terminate this Agreement.

 

12.5 Disputes regarding Termination.
If COMPANY disputes any termination by M.I.T. under this Section, it must notify M.I.T. of the nature of such dispute and the proposed
manner in which to resolve the dispute within fifteen (15) business days of receipt of notification of breach or notification of
termination by M.I.T., whichever is sooner. If the parties do not resolve such dispute within ten (10) days of such notification,
then COMPANY shall be required to initiate the dispute resolution procedures outlined in Section 13.3(a) immediately. If it does
not do so, COMPANY shall be considered to have waived its rights to dispute the termination.

 

    	45

    	 

    

 

12.6 Effect of Termination.

 

(a)          Survival.
The following provisions shall survive the expiration or termination of this Agreement:

 

		§	Article 1 (“Definitions”);

		§	Article 8 (“Indemnification and Insurance”); 

		§	Article 9 (“No Representations or Warranties”);

		§	Article 13 (“Dispute Resolution”); 

		§	Article 14 (“Miscellaneous”); 

		§	Section 4.1(c) (“Running Royalties”)

		§	Section 4.1(g) (“Milestone Payments”)

		§	Section 4.1(h) (“Sharing of Consideration Related to DISCOVERED
PRODUCTS”)

		§	Section 4.1(k) (“Consideration for Grant of Rights”>>“Equity”)

		§	Section 5.2 (“Content of Reports and Payments”); 

		§	Section 5.4 (“Records”); 

		§	Section 11.1 (“Compliance With Laws”);

		§	Section 11.2 (“Export Control”); and

		§	Section 12.6 (“Effect of Termination”). 

 

(b)          Pre-termination
Obligations. In no event shall termination of this Agreement release COMPANY, AFFILIATES, or SUBLICENSEES from the obligation
to pay any amounts that became due on or before the effective date of termination.

 

(c)          Discovered
Products. The termination of this Agreement shall not affect the rights of the COMPANY to make, use, sell, offer to sell, import,
DISCOVERED PRODUCTS solely to the extent that the manufacture, use, sale, offer for sale, or import of such DISCOVERED PRODUCTS
would not infringe one or more claims of the PATENT RIGHTS, and provided that COMPANY and its AFFILIATES comply with the applicable
terms of this Agreement with respect to DISCOVERED PRODUCTS. For clarity, COMPANY and its AFFILIATES will not have any rights under
the PATENT RIGHTS after termination of this Agreement.

 

    	46

    	 

    

 

13. DISPUTE
RESOLUTION.

 

13.1 Mandatory Procedures. The parties
agree that any dispute arising out of or relating to this Agreement shall be resolved solely by means of the procedures set forth
in this Article, and that such procedures constitute legally binding obligations that are an essential provision of this Agreement.
If either party fails to observe the procedures of this Article, as may be modified by their written agreement, the other party
may bring an action for specific performance of these procedures in any court of competent jurisdiction.

 

13.2 Equitable Remedies. Although
the procedures specified in this Article are the sole and exclusive procedures for the resolution of disputes arising out of or
relating to this Agreement, either party may seek a preliminary injunction or other provisional equitable relief if, in its reasonable
judgment, such action is necessary to avoid irreparable harm to itself or to preserve its rights under this Agreement.

 

13.3 Dispute Resolution Procedures.

 

(a)          Mediation. In the event of
any dispute arising out of or relating to this Agreement, either party may initiate mediation upon written notice to the other
party ("Notice Date") pursuant to Section 14.1, whereupon both parties shall be obligated to engage in a mediation proceeding.
The mediation shall commence within forty-five (45) days of the Notice Date. The mediation shall be conducted by a single mediator
in Boston, Massachusetts. The party requesting mediation shall designate two (2) or more nominees for mediator in its notice. The
other party may accept one of the nominees or may designate its own nominees by notice addressed to the American Arbitration Association
(AAA) and copied to the requesting party. If within, fifteen (15) days following the request for mediation, the parties have not
selected a mutually acceptable mediator, a mediator shall be appointed by the AAA according to the Commercial Mediation Rules.
The mediator shall attempt to facilitate a negotiated settlement of the dispute, but shall have no authority to impose any settlement
terms on the parties. The expenses of the mediation shall be borne equally by the parties, but each party shall be responsible
for its own counsel fees and expenses.

 

(b)          Trial Without Jury. If the
dispute is not resolved by mediation within forty-five (45) days after commencement of mediation, each party shall have the right
to pursue any other remedies legally available to resolve the dispute, provided, however, that the parties expressly waive any
right to a jury trial in any legal proceeding under this Article.

 

    	47

    	 

    

 

13.4 Performance to Continue. Each
party shall continue to perform its undisputed obligations under this Agreement pending final resolution of any dispute arising
out of or relating to this Agreement; provided, however, that a party may suspend performance of its undisputed obligations during
any period in which the other party fails or refuses to perform its undisputed obligations. Nothing in this Article is intended
to relieve COMPANY from its obligation to make undisputed payments pursuant to Articles 4 and 6 of this Agreement.

 

13.5 Statute of Limitations. The
parties agree that all applicable statutes of limitation and time-based defenses (including, but not limited to, estoppel and laches)
shall be tolled while the procedures set forth in Sections 13.3(a) are pending. The parties shall cooperate in taking any actions
necessary to achieve this result.

 

13.6 HHMI. Notwithstanding the foregoing,
any disputes affecting the rights or property of HHMI shall not be subject to any of the provisions of Sections 13.1 through 13.5.

 

14. MISCELLANEOUS.

 

14.1 Notice. Any notices required
or permitted under this Agreement shall be in writing, shall specifically refer to this Agreement, and shall be sent by hand, recognized
national overnight courier, confirmed facsimile transmission, confirmed electronic mail, or registered or certified mail, postage
prepaid, return receipt requested, to the following addresses or facsimile numbers of the parties:

 

If to M.I.T., for all matters relating
to the license:

 

	 	Massachusetts Institute of Technology
	 	Technology Licensing Office, Room NE18-501
	 	One Cambridge Center, Kendall Square
	 	Cambridge, MA 02142-1601
	 	Attention: Director
	 	Tel:    617-253-6966
	 	Fax:    617-258-6790

 

If to M.I.T., relating to any EQUITY action
after the initial issuance of shares:

 

	 	Massachusetts Institute of Technology
	 	Treasurer's Office
	 	238 Main Street
	 	Cambridge, MA  02142
	 	Attention:  Marianthe Mewkill
	 	Tel:    617-253-5422
	 	Fax:    617-258-6676

 

    	48

    	 

    

 

	If to COMPANY:	Enumeral Biomedical Corp.
	 	1450 Broadway, 24th Floor
	 	New York, New York 10018
	 	Attention: Arthur Tinkelenberg
	 	Tel:   347-277-4787
	 	Email:  arthur@enumeral.com

 

If, to COMPANY, notices regarding financial
matters, including invoices:

 

	 	Contact Name: Arthur Tinkelenberg
	 	Department: Enumeral Biomedical Corp.
	 	Address: 1450 Broadway, 24th Floor
	 	New York, New York 10018
	 	Tel: 347-277-4787
	 	Email: arthur@enumeral.com

 

If to HARVARD:

	 	Office of Technology Development
	 	Harvard University
	 	Holyoke Center 727
	 	1350 Massachusetts Avenue
	 	Cambridge, Massachusetts 02138
	 	Fax: (617) 495-9568
	 	Attn:  Chief Technology Development Officer

 

All notices under this Agreement shall be
deemed effective upon receipt. A party may change its contact information immediately upon written notice to the other party in
the manner provided in this Section.

 

14.2 Governing Law/Jurisdiction.
This Agreement and all disputes arising out of or related to this Agreement, or the performance, enforcement, breach or termination
hereof, and any remedies relating thereto, shall be construed, governed, interpreted and applied in accordance with the laws of
the Commonwealth of Massachusetts, U.S.A., without regard to conflict of laws principles, except that questions affecting the construction
and effect of any patent shall be determined by the law of the country in which the patent shall have been granted. The state and
federal courts having jurisdiction over Cambridge, MA, USA, provide the exclusive forum for any PATENT CHALLENGE and/or any court
action between the parties relating to this Agreement. COMPANY submits to the jurisdiction of such courts and waives any claim
that such court lacks jurisdiction over COMPANY or its AFFILIATES or constitutes an inconvenient or improper forum.

 

    	49

    	 

    

 

14.3 Force Majeure. Neither party
will be responsible for delays resulting from causes beyond the reasonable control of such party, including without limitation
fire, explosion, flood, war, strike, or riot, provided that the nonperforming party uses commercially reasonable efforts to avoid
or remove such causes of nonperformance and continues performance under this Agreement with reasonable dispatch whenever such causes
are removed.

 

14.4 Amendment and Waiver. This Agreement
may be amended, supplemented, or otherwise modified only by means of a written instrument signed by both parties. Any waiver of
any rights or failure to act in a specific instance shall relate only to such instance and shall not be construed as an agreement
to waive any rights or fail to act in any other instance, whether or not similar.

 

14.5 Severability. In the event that
any provision of this Agreement shall be held invalid or unenforceable for any reason, such invalidity or unenforceability shall
not affect any other provision of this Agreement, and the parties shall negotiate in good faith to modify the Agreement to preserve
(to the extent possible) their original intent. If the parties fail to reach a modified agreement within thirty (30) days after
the relevant provision is held invalid or unenforceable, then the dispute shall be resolved in accordance with the procedures set
forth in Article 13. While the dispute is pending resolution, this Agreement shall be construed as if such provision were deleted
by agreement of the parties.

 

14.6 Binding Effect. This Agreement
shall be binding upon and inure to the benefit of the parties and their respective permitted successors and assigns.

 

14.7 Headings. All headings are for
convenience only and shall not affect the meaning of any provision of this Agreement.

 

14.8 HHMI. HHMI is not a party to
this Agreement and has no liability to any licensee, sublicensee, or user of any technology covered by this Agreement, but HHMI
is an intended third-party beneficiary of this Agreement and certain of its provisions are for the benefit of HHMI and are enforceable
by HHMI in its own name.

 

14.9 Entire Agreement. This Agreement
constitutes the entire agreement between the parties with respect to its subject matter and supersedes all prior agreements or
understandings between the parties relating to its subject matter.

 

[Signature Page
Follows]

 

    	50

    	 

    

 

IN WITNESS WHEREOF, the parties have caused
this Agreement to be executed by their duly authorized representatives.

 

The EFFECTIVE DATE of this Agreement is April 15, 2011.

 

	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	 	ENUMERAL BIOMEDICAL CORP.
	 	 	 
	By: /s/ Lita L. Nelsen	 	 
	Name: Lita L. Nelsen	 	By: /s/ Arthur H. Tinkelenberg
	Title:Director of Technology Licensing Office	 	Name: Arthur H. Tinkelenberg
	 	 	Title: President & CEO
	MASSACHUSETTS INSTITUTE OF	 	 
	TECHNOLOGY	 	 
	 	 	 
	By: /s/ Claude R. Canizares	 	 
	Name: 	Claude R. Canizares, Ph.D.	 	 
	Title:	Bruno Rossi Professor of Experimental Physics,	 	 
	 	Vice President for Research, and	 	 
	 	Associate Provost	 	 
	 	 	 
	WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH	 	 
	 	 	 
	By: /s/ Martin A. Mullins	 	 
	Name: Martin A. Mullins	 	 
	Title: Vice President	 	 

 

    	51

    	 

    

 

APPENDIX
A

List of Patent Applications and Patents

 

I.           United
States Patents and Applications

 

M.I.T. Case No. 13529

United States of America Serial No. 12/911642, Filed October
22, 2010

"Method For Detecting Active And Latent Virally Infected
Cells"

by Yuan Gong and John Christopher. Love

 

M.I.T. Case No. 13627

United States of America Serial No. 12/390279, Filed February
20, 2009

"Microarray With Microchannels"

by John Christopher Love, Eliseo Papa and Craig M. Story

 

II.          International
(non-U.S.) Patents and Applications

 

M.I.T. Case No. 12967W

Patent Cooperation Treaty Serial No. US2009/003354, Filed June
1, 2009

"Compositions And Methods For Spatial Separation And Screening
Of Cells"

by John Christopher Love and Kerry Routenberg Love

 

M.I.T. Case No. 13528

Patent Cooperation Treaty Serial No. PCT/US2009/066876, Filed
December 4, 2009

"Method For Diagnosing Allergic Reactions"

by Qing Han, John Christopher Love and Vinay Tripuraneni

 

M.I.T. Case No. 13546

Canada Serial No. 2689681, Filed July 13, 2009

Patent Cooperation Treaty Serial No. PCT/US2009/50411, Filed
July 13, 2009

"Compositions And Methods For Assessing Cytotoxicity Of
Single Cells"

by Boris Julg, John Christopher Love and Navin Varadarajan

 

M.I.T. Case No. 13627

Patent Cooperation Treaty Serial No. PCT/US2010/024733, Filed
February 19, 2010

"Microarray With Microchannels"

by John Christopher Love, Eliseo Papa and Craig M. Story

 

    	52

    	 

    

 

APPENDIX
B

 

List of Countries (excluding United States)
for which

PATENT RIGHTS Applications Will Be Filed,
Prosecuted and Maintained

 

It is expected that PATENT RIGHTS will be filed in:

 

*

 

It is understood by both parties, however, that country filing
assessments must properly be made on a case by case basis, and some modifications of this list may be appropriate for particular
cases.

 

    	53

    	 

    

 

APPENDIX
C

 

Form of Non-Exclusive License for the
RESEARCH MARKET

 

Dear Scientist:

 

This Enumeral [gadget name] is provided to you under a LIMITED
USE NONEXCLUSIVE LICENSE. The product and many of its uses are patented; any use of this product except in accordance with this
license will constitute an infringement of our patents.

This license is granted only under the following conditions
and will be void if such conditions are not met:

 

		1.	The [gadget name] will be used only for research in a not-for-profit
organization and only under funding by not-for-profit organizations, including the US government.

		2.	Specifically, the [gadget name] will not be used for research
or services funded by any for-profit company, or for research from which any intellectual property is promised to any for-profit
company.

		3.	The [gadget name] will not be used for clinical diagnostic
purposes in human or veterinary medicine.

		4.	The [gadget name] will not be transferred to any other
organization than your own.

		5.	Any transfer of the [gadget name] to another laboratory
in your organization will be accompanied by a copy of this LIMITED USE license and any investigator to whom you will transfer
the [gadget name] and who uses the [gadget name] will be bound by these obligations.

 

In addition:

 

		6.	In any publications arising from the use of the [gadget
name] if it is appropriate that the methods used in the research are described, you will refer to the [gadget name] as “____________________,
provided by Enumeral Biomedical Corp.”

 

[Enumeral may include any appropriate disclaimers and non-warranty
of fitness for use, but NOT indemnification by the non-profit research institution.]

 

    	54

    	 

    

 

APPENDIX
D

 

COMPANY Diligence Obligations Upon Assignment
of the Agreement

 

In the event of an assignment as described in Article 10, the
Diligence Requirements set forth in Section 3.1 shall be replaced in their entirety with the following:

 

Diligence Requirements. COMPANY shall
use commercially reasonable diligent efforts, or shall cause its AFFILIATES to use commercially reasonable diligent efforts, to
develop LICENSED PRODUCTS, DISCOVERED PRODUCTS or LICENSED PROCESSES and to introduce LICENSED PRODUCTS, DISCOVERED PRODUCTS or
LICENSED PROCESSES into the commercial market; thereafter, COMPANY or its AFFILIATES shall make LICENSED PRODUCTS, DISCOVERED PRODUCTS
or LICENSED PROCESSES reasonably available to the public. Specifically, COMPANY or AFFILIATE shall fulfill the following obligations:

 

(a) Within * after the effective date of assignment
of this Agreement, COMPANY shall furnish M.I.T. with a written research and development plan describing the major tasks to be achieved
in order to bring to market a LICENSED PRODUCT, DISCOVERED PRODUCT or a LICENSED PROCESS, specifying the number of staff and other
resources to be devoted to such commercialization effort.

 

(b) Within * after the end of each calendar
year, COMPANY shall furnish M.I.T. with a written report (consistent with Section 5.1(a)) on the progress of its efforts during
the immediately preceding calendar year to develop and commercialize LICENSED PRODUCTS, DISCOVERED PRODUCTS or LICENSED PROCESSES.
The report shall also contain a discussion of intended efforts and sales projections for the year in which the report is submitted.

 

(c) COMPANY or an AFFILIATE shall expend at
least * on research toward the development of LICENSED PRODUCTS, LICENSED PROCESSES and/or DISCOVERED PRODUCTS in each calendar
year (pro-rated for partial years) beginning upon the effective date of assignment of this Agreement and ending with the first
commercial sale of a THERAPEUTIC PRODUCT or DIAGNOSTIC PRODUCT by COMPANY or an AFFILIATE.

 

(d) Within * of the effective date of assignment
of this Agreement, COMPANY or an AFFILIATE shall enter into at least * bona fide sublicenses and/or CORPORATE PARTNER agreements
for the development of THERAPEUTIC PRODUCTS and/or DIAGNOSTIC PRODUCTS.

 

(e) Within * of the effective date of assignment
of this Agreement, in the aggregate, COMPANY or an AFFILIATE shall enter into at least * bona fide sublicenses and/or CORPORATE
PARTNER agreements for the development of THERAPEUTIC PRODUCTS and/or DIAGNOSTIC PRODUCTS.

 

(f) Within * of the effective date of assignment
of this Agreement, COMPANY or an AFFILIATE shall commence a Phase 2 clinical trial of a THERAPEUTIC PRODUCT.

 

    	55

    	 

    

 

(g) Within * of the effective date of assignment
of this Agreement, COMPANY or an AFFILIATE shall make a first commercial sale of a THERAPEUTIC PRODUCT.

 

(h) Within *of the effective date of assignment
of this Agreement, COMPANY or an AFFILIATE shall make a first commercial sale of a DIAGNOSTIC PRODUCT.

 

(i) Within * of the effective date of assignment
of this Agreement, a SUBLICENSEE or CORPORATE PARTNER shall make a first commercial sale of a DIAGNOSTIC PRODUCT.

 

(j) Within * of the effective date of assignment
of this Agreement, a SUBLICENSEE or CORPORATE PARTNER shall commence a Phase 2 clinical trial of a THERAPEUTIC PRODUCT.

 

(k) Within * of the effective date of assignment
of this Agreement, a SUBLICENSEE or CORPORATE PARTNER shall make a first commercial sale of a THERAPEUTIC PRODUCT.

 

(l) Within * of the effective date of assignment
of this Agreement, COMPANY shall permit an in-plant inspection by M.I.T., and thereafter permit in-plant inspections by M.I.T.
at regular intervals with at least six (6) months between each such inspection.

 

(m) As of the effective date of assignment
of this Agreement, COMPANY or an AFFILIATE or SUBLICENSEE shall continue to make an APPARATUS PRODUCT commercially available to
the RESEARCH MARKET * to meet the demand of the RESEARCH MARKET, including maintaining an on hand inventory of APPARATUS PRODUCTS
sufficient to fulfill customer orders without delay.

 

(n) COMPANY or an AFFILIATE or SUBLICENSEE
shall make APPARATUS PRODUCTS available for use by non-profit research institutions without restrictions, for example, without
reach-through rights to discoveries made through use of LICENSED PRODUCTS and LICENSED PROCESSES, under a non-exclusive license
substantially similar to the form set forth in Appendix C.

 

In the event that M.I.T. determines that
COMPANY (or an AFFILIATE) has failed to fulfill any of its obligations under this Section 3.1, then M.I.T. may treat such failure
as a material breach in accordance with Section 12.3(b).

 

    	56

    	 

    

 

EXHIBIT
A-1

 

CONFLICT
AVOIDANCE STATEMENT

 

 

Name: John Christopher Love

 

Dept. or Lab: Chemical Engineering

 

		Company:	Enumeral Technologies, Inc.

		Address:	1450 Broadway, 24th Floor

New York, NY 10018

 

Licensed Technology:

 

M.I.T. Case No. 12393Q, "Screening
Assays and Methods", by John Christopher. Love, No Inventor and Jehnna Ronan

 

M.I.T. Case No. 12967W, "Method
for Screening Libraries of Enzymes with Improved Catalytic Properties or Altered Substrate Specificity Using Microwells for the
Spatial Separation of Cells Producing the Enzymes", by John Christopher. Love and Kerry Routenberg. Love

 

M.I.T. Case No. 13528, "Method
for Diagnosing Allergic Reactions", by Qing Han, John Christopher. Love and Vinay Tripuraneni

 

M.I.T. Case No. 13529, "Method
for Detecting Active and Latent Virally Infected Cells", by Yuan Gong and John Christopher. Love

 

M.I.T. Case No. 13546, "Method
for Assessing Cytotoxicity of Single Cells", by Boris Julg, John Christopher. Love and Navin Varadarajan

 

M.I.T. Case No. 13627, "Composition
of an Array of Microwells with an Integrated Microfluidic System", by John Christopher. Love, Eliseo Papa and Craig M. Story

 

Because of the M.I.T. license granted to the above company and
my equity* position with this company, I acknowledge the potential for a possible conflict of interest between the performance
of research at M.I.T. and my contractual or other obligations to this company. Therefore, I will not:

 

		1)	use students at M.I.T. for research and development projects for the company;

 

		2)	restrict or delay access to information from my M.I.T. research;

 

		3)	take direct or indirect research support from the company in order to support my activities at M.I.T.; or

 

		4)	employ students at the company, except in accordance with Section 4.5.2, “Faculty and Students,” in the Policies
and Procedures Guide.

 

    	 

    	 

    

 

In addition, in order to avoid the appearance of a conflict,
I will attempt to differentiate clearly between the intellectual directions of my M.I.T. research and my contributions to the company.
To that end, I will expressly inform my department head/laboratory director annually of the general nature of my activities on
behalf of the company.

 

	 	Signed: /s/ John Christopher Love
	 	Date: 4/14/11

 

Approved by: /s/ Klaus F. Jensen

 

Name (print): Klaus F. Jensen

(Dept. Head or Lab Dir)

 

* "Equity" includes stock, options, warrants
or other financial instruments convertible into stock, which are directly or indirectly controlled by the inventor.

 

    	2

    	 

    

 

EXHIBIT A-2

 

CONFLICT
AVOIDANCE STATEMENT

 

 

Name: Kerry Routenberg Love

 

Dept. or Lab: Chemical Engineering

 

		Company:	Enumeral Technologies, Inc.

		Address:	1450 Broadway, 24th Floor

New York, NY 10018

 

Licensed Technology:

 

M.I.T. Case No. 12393Q, "Screening
Assays and Methods", by John Christopher. Love, No Inventor and Jehnna Ronan

 

M.I.T. Case No. 12967W, "Method
for Screening Libraries of Enzymes with Improved Catalytic Properties or Altered Substrate Specificity Using Microwells for the
Spatial Separation of Cells Producing the Enzymes", by John Christopher. Love and Kerry Routenberg. Love

 

M.I.T. Case No. 13528, "Method
for Diagnosing Allergic Reactions", by Qing Han, John Christopher. Love and Vinay Tripuraneni

 

M.I.T. Case No. 13529, "Method
for Detecting Active and Latent Virally Infected Cells", by Yuan Gong and John Christopher. Love

 

M.I.T. Case No. 13546, "Method
for Assessing Cytotoxicity of Single Cells", by Boris Julg, John Christopher. Love and Navin Varadarajan

 

M.I.T. Case No. 13627, "Composition
of an Array of Microwells with an Integrated Microfluidic System", by John Christopher. Love, Eliseo Papa and Craig M. Story

 

Because of the M.I.T. license granted to the above company and
my equity* position with this company, I acknowledge the potential for a possible conflict of interest between the performance
of research at M.I.T. and my contractual or other obligations to this company. Therefore, I will not:

 

		1)	use students at M.I.T. for research and development projects for the company;

 

		2)	restrict or delay access to information from my M.I.T. research;

 

		3)	take direct or indirect research support from the company in order to support my activities at M.I.T.; or

 

		4)	employ students at the company, except in accordance with Section 4.5.2, “Faculty and Students,” in the Policies
and Procedures Guide.

 

    	3

    	 

    

 

In addition, in order to avoid the appearance of a conflict,
I will attempt to differentiate clearly between the intellectual directions of my M.I.T. research and my contributions to the company.
To that end, I will expressly inform my department head/laboratory director annually of the general nature of my activities on
behalf of the company.

 

	 	Signed: /s/ Kerry Love
	 	Date: April 14, 2011

 

Approved by: /s/ Klaus F. Jensen

 

Name (print): Klaus F. Jensen

(Dept. Head or Lab Dir)

 

* "Equity" includes stock, options, warrants
or other financial instruments convertible into stock,

which are directly or indirectly controlled by the inventor.

 

    	4

    	 

    

 

EXHIBIT B-1

 

INVENTOR/AUTHOR ACKNOWLEDGMENT OF
NO EQUITY DISTRIBUTION

Form Version 7/14/2010

 

In partial reliance on the undersigned’s
execution of this Acknowledgment, M.I.T. has entered into the license agreement to which this Acknowledgment is attached (the “LICENSE”)
in which COMPANY received certain licenses to the technology listed below, on some or all of which the undersigned is a listed
inventor or author. The undersigned, independently of the LICENSE, has received or will soon acquire equity in Enumeral Technologies,
Inc. (“COMPANY”), and, in accordance with M.I.T.’s licensing policies contained in M.I.T.'s Guide to the Ownership,
Distribution and Commercial Development of M.I.T. Technology, as that policy may be amended from time to time (specifically
§4.10.2 as of this Form Version date), the undersigned, on his/her own behalf and on behalf of his/her heirs and assigns,
acknowledges and agrees that he/she has no right to receive any share of equity income received by M.I.T. in consideration for
the LICENSE.

 

Technology Licensed as of the EFFECTIVE
DATE of the LICENSE:

 

M.I.T. Case No. 12393Q, "Screening
Assays and Methods", by John Christopher. Love, No Inventor and Jehnna Ronan

 

M.I.T. Case No. 12967W, "Method
for Screening Libraries of Enzymes with Improved Catalytic Properties or Altered Substrate Specificity Using Microwells for the
Spatial Separation of Cells Producing the Enzymes", by John Christopher. Love and Kerry Routenberg. Love

 

M.I.T. Case No. 13528, "Method
for Diagnosing Allergic Reactions", by Qing Han, John Christopher. Love and Vinay Tripuraneni

 

M.I.T. Case No. 13529, "Method
for Detecting Active and Latent Virally Infected Cells", by Yuan Gong and John Christopher. Love

 

M.I.T. Case No. 13546, "Method
for Assessing Cytotoxicity of Single Cells", by Boris Julg, John Christopher. Love and Navin Varadarajan

 

M.I.T. Case No. 13627, "Composition
of an Array of Microwells with an Integrated Microfluidic System", by John Christopher. Love, Eliseo Papa and Craig M. Story

 

	Witness: /s/ Kerry Love	Signed: /s/ John Christopher Love
	 	Print Name: John Christopher Love
	 	 
	 	Date: 4/14/11

 

    	5

    	 

    

 

EXHIBIT B-2

 

INVENTOR/AUTHOR ACKNOWLEDGMENT OF
NO EQUITY DISTRIBUTION

Form Version 7/14/2010

 

In partial reliance on the undersigned’s
execution of this Acknowledgment, M.I.T. has entered into the license agreement to which this Acknowledgment is attached (the “LICENSE”)
in which COMPANY received certain licenses to the technology listed below, on some or all of which the undersigned is a listed
inventor or author. The undersigned, independently of the LICENSE, has received or will soon acquire equity in Enumeral Technologies,
Inc. (“COMPANY”), and, in accordance with M.I.T.’s licensing policies contained in M.I.T.'s Guide to the Ownership,
Distribution and Commercial Development of M.I.T. Technology, as that policy may be amended from time to time (specifically
§4.10.2 as of this Form Version date), the undersigned, on his/her own behalf and on behalf of his/her heirs and assigns,
acknowledges and agrees that he/she has no right to receive any share of equity income received by M.I.T. in consideration for
the LICENSE.

 

Technology Licensed as of the EFFECTIVE
DATE of the LICENSE:

 

M.I.T. Case No. 12393Q, "Screening
Assays and Methods", by John Christopher. Love, No Inventor and Jehnna Ronan

 

M.I.T. Case No. 12967W, "Method
for Screening Libraries of Enzymes with Improved Catalytic Properties or Altered Substrate Specificity Using Microwells for the
Spatial Separation of Cells Producing the Enzymes", by John Christopher. Love and Kerry Routenberg. Love

 

M.I.T. Case No. 13528, "Method
for Diagnosing Allergic Reactions", by Qing Han, John Christopher. Love and Vinay Tripuraneni

 

M.I.T. Case No. 13529, "Method
for Detecting Active and Latent Virally Infected Cells", by Yuan Gong and John Christopher. Love

 

M.I.T. Case No. 13546, "Method
for Assessing Cytotoxicity of Single Cells", by Boris Julg, John Christopher. Love and Navin Varadarajan

 

M.I.T. Case No. 13627, "Composition
of an Array of Microwells with an Integrated Microfluidic System", by John Christopher. Love, Eliseo Papa and Craig M. Story

 

	Witness: /s/ John Christopher Love	Signed: /s/ Kerry Routenberg Love
	 	Print Name: Kerry Routenberg Love
	 	 
	 	Date: 4/14/11	 

 

    	6FIRST AMENDMENT

 

This First Amendment, effective as of the
date set forth above the signatures of the parties below, amends the Exclusive Patent License Agreement dated April 15, 2011 (the
“LICENSE AGREEMENT”) between the Massachusetts Institute of Technology, a Massachusetts corporation having its principal
office at 77 Massachusetts Avenue, Cambridge, Massachusetts 02139 (“M.I.T.”), and Enumeral Biomedical Corp., a Delaware
corporation having its principal place of business at 1450 Broadway, 24th Floor, New York, NY 10018 (“COMPANY”).

 

WHEREAS, M.I.T. and COMPANY wish to amend
the LICENSE AGREEMENT to clarify how equity issuances are to be made under the LICENSE AGREEMENT;

 

NOW, THEREFORE, in consideration of the
promises and mutual covenants contained herein, the parties hereby agree as follows:

 

1.     Section
4.1(k) of the LICENSE AGREEMENT shall be deleted and replaced in its entirety with the following:

 

(k)   Equity.

 

(i)          Initial
Grant. COMPANY shall issue a total of Sixty Six Thousand Three Hundred and Three (66,303) shares of Common Stock of COMPANY,
$0.0001 par value per share, (the “Shares”) to M.I.T., WHITEHEAD, HARVARD and HOSPITAL, collectively the “Shareholders”),
in the amounts as M.I.T. shall direct. Such issuances shall be recorded on the Stock Transfer Ledger of COMPANY on the EFFECTIVE
DATE and the Shares shall be delivered to the Shareholders within thirty (30) days of the EFFECTIVE DATE.

 

COMPANY represents to M.I.T. that,
as of the EFFECTIVE DATE, the aggregate number of Shares equals Three Percent (3%) of the COMPANY’s issued and outstanding
Common Stock calculated on a “Fully Diluted Basis.” For purposes of this Section 4.1(k), “Fully Diluted Basis”
shall mean the total number of issued and outstanding shares of the COMPANY’s Common Stock calculated to include conversion
of all issued and outstanding securities convertible into Common Stock, the exercise of all outstanding options and warrants to
purchase shares of Common Stock, whether or not then exercisable, and the conversion or exercise of all rights to purchase or acquire
Common Stock, whether or not then convertible or exercisable. Notwithstanding the foregoing, for purposes of calculating the COMPANY’s
issued and outstanding Fully Diluted Common Stock, all Convertible Notes issued prior to the close of the COMPANY’s initial
equity financing shall be excluded until the date of their conversion, at which time sufficient shares will be issued by COMPANY
to the Shareholders to maintain their aggregate ownership at Three Percent (3%) as described in this Section.

 

(ii)         Anti-Dilution
Protection Through Funding Threshold. COMPANY from time to time shall issue additional shares of Common Stock to the Shareholders,
pro rata in accordance with their respective ownership of the Shares, as may be necessary to ensure that the Shares (together with
any and all shares issued pursuant to this Section 4.1(k)(ii)) continue to represent in the aggregate at least Three Percent (3%)
of the COMPANY’s issued and outstanding Common Stock calculated on a Fully Diluted Basis, as calculated after giving effect
to the anti-dilutive issuance. Such issuances shall continue until and including the date upon which a total of Seven Million Five
Hundred Thousand Dollars ($7,500,000) in cash in exchange for COMPANY’s capital stock (the “Funding Threshold”)
shall be received by COMPANY. Thereafter, no additional shares shall be due to the Stockholders pursuant to this section.

 

    	Page 1 of 5

    	 

    

  

(iii)        Participation
in Private Equity Offerings After Funding Threshold. After the date of the Funding Threshold, each of the Shareholders shall
have the right to purchase additional shares of COMPANY’s capital stock in any private offering by the COMPANY of such capital
stock in exchange for cash (“OFFERING”), to maintain its pro rata ownership as calculated immediately prior to such
offering on a Fully Diluted Basis, pursuant to the terms and conditions at least as favorable as those granted to the other offerees.
All rights granted to the Shareholders pursuant to this Section 4.1(k)(iii) shall terminate immediately (i) prior to a firm commitment
underwritten public offering of the COMPANY’s common stock resulting in gross proceeds to the COMPANY of at least $10 million.
This right granted to the Shareholders shall not apply to any equity issued to any lender, the issuance of any shares in connection
with the conversion of any equity securities, the issuance of securities to a collaboration partner or joint venture, or the issuance
of any securities under any equity incentive plan.

 

(iv)         Adjustments
for Punitive Round Financings. After the date of the Funding Threshold (the “Funding Threshold Date”), if COMPANY
takes any action that is a Dilutive Issuance (as defined below), then immediately following such Dilutive Issuance, COMPANY shall
issue to the Shareholders additional shares of Common Stock such that the Institution Share Number (as defined below) equals the
product obtained by multiplying the Institution Share Number in effect immediately before the Dilutive Issuance by the Adjustment
Fraction defined below. The Institution Share Price in effect immediately after the Dilutive Issuance shall be adjusted to equal
the result obtained by dividing the Institution Share Price in effect immediately before the Dilutive Issuance by the Adjustment
Fraction defined below.

 

	
         Adjustment Fraction equals:
	
        (A + C)

        (A + B)

 

where:

 

A = the number of shares of Common Stock
issued and outstanding on a Fully Diluted Basis immediately prior to the Dilutive Issuance

 

B = the number of shares of Common Stock
that could be purchased at the Institution Share Price immediately prior to the Dilutive Issuance using the aggregate consideration
received by COMPANY in connection with the Dilutive Issuance.

 

For purposes of calculation of “B”,
if the Dilutive Issuance is as described in subpart (III) of the definition of Dilutive Issuance below, the aggregate consideration
received by COMPANY shall be the price per share at the applicable Convertible Instrument (as defined below) immediately following
the Dilutive Issuance (as adjusted for the Dilutive Issuance pursuant to the terms and conditions of the Convertible Instrument
or the COMPANY’s Certificate of Incorporation or other applicable formation document) multiplied by the total number of shares
of Capital Stock (as defined below) into which such newly adjusted Convertible Instrument could be exercised or converted, whether
or not then exercisable or convertible.

 

    	Page 2 of 5

    	 

    

  

C = the number of shares of Capital Stock
issued on a Fully Diluted Basis pursuant to the Dilutive Issuance, or, if a Convertible Instrument is issued in the Dilutive Issuance,
the number of shares of Capital Stock issuable on a Fully Diluted Basis if all shares of the Convertible Instrument were converted
into the applicable Capital Stock, whether or not then exercisable or convertible.

 

For purposes of calculation of “C”,
if the Dilutive Issuance is as described in subpart (III) of the definition of Dilutive Issuance below, then C shall be the total
number of shares of Capital Stock into which the newly adjusted Convertible Instrument could be exercised or converted, whether
or not then exercisable or convertible.

 

The following definitions shall apply to
this Section 4.1(k)(iv):

 

“Capital Stock” shall mean any
form of COMPANY’s capital stock.

 

“Convertible Instrument” shall
mean any instrument issued by COMPANY that is convertible into, or may be exercised in exchange for, any Capital Stock.

 

“Dilutive Issuance” shall mean
any issuance of Capital Stock or any Convertible Instrument by COMPANY where such issuance results in (I) the price per share of
COMPANY’s Common Stock being reduced to less than the current Institution Share Price (as defined in this subsection), (II)
the price per share of any Convertible Instrument being reduced to less than the price of the same series or type of Convertible
Instrument in the most recently preceding offering and sale of such Convertible Instrument, or (III) the conversion ratio of any
Convertible Instrument changing such that each previously issued share of such Convertible Instrument becomes convertible into
a greater number of shares of the applicable Capital Stock.

 

“Institution Share Number” shall
mean the number of shares of COMPANY’s Common Stock that the Shareholders own on the date of the Dilutive Issuance, as adjusted
from time to time pursuant to this section. Notwithstanding the foregoing, any shares of Common Stock acquired by the Shareholders
pursuant to Section 4.1(k)(iii) shall not be included in the Institution Share Number.

 

“Institution Share Price” shall
mean the value per share of the shares of Common Stock included in the Institution Share Number, as adjusted from time to time
pursuant to this section. For purposes of this section, the initial Institution Share Price to be used in an adjustment resulting
from the first Dilutive Issuance to occur after the Funding Threshold Date shall be the Fair Market Value per share of the Common
Stock of the COMPANY effective on the Funding Threshold Date.

 

“Fair Market Value” of a share
of Common Stock shall be the highest price per share that the COMPANY could obtain from a willing buyer (not a current employee
or director) for shares of Common Stock sold by the COMPANY, from authorized but unissued shares, as determined in good faith by
the Board of Directors of the COMPANY, unless the COMPANY shall become subject to a merger, acquisition or other consolidation
pursuant to which the COMPANY is not the surviving party, in which case the current fair market value of a share of Common Stock
shall be deemed to be the value received by the holders of the COMPANY’s Common Stock for each share of Common Stock pursuant
to the COMPANY’s acquisition.

 

    	Page 3 of 5

    	 

    

 

(v)          Massachusetts
General Hospital. If HOSPITAL’s ownership of HOSPITAL’s shares shall at any time create a conflict of interest
affecting HOSPITAL’s ability to conduct clinical trials, clinical studies, clinical research or clinical validation or if
HOSPITAL shall otherwise be required to divest itself of HOSPITAL’s shares due to law or HOSPITAL’s conflict of interest
policies, then HOSPITAL shall have the right to elect to sell (“TRANSFER”) the HOSPITAL’s shares to any third
party (“PROPOSED TRANSFEREE”) free of any restriction and free of any co-sale rights, tag along rights, of COMPANY
or its stockholders or investors provided however the HOSPITAL shall not transfer the HOSPITAL’s shares to a COMPETING ORGANIZATION
or to an investor in any COMPETING ORGANIZATION. Such third party investor shall agree to execute any and all investment documents
binding on the HOSPITAL. Notwithstanding the foregoing, the COMPANY first and then the other stockholders of the COMPANY shall
have the right of first refusal to purchase such shares at the price offered to such third party by the HOSPITAL pursuant to the
following conditions. HOSPITAL shall first offer to sell to the COMPANY or any Persons designated by the Company as the “Purchaser”
hereunder (the COMPANY or such designees being referred to as the “DESIGNATED PURCHASER”) the HOSPITAL’s shares
that the HOSPITAL desires to sell (the “OFFERED SECURITIES”), at the same price and on the terms identical in all material
respects to those terms that the HOSPITAL intends to sell the Offered Securities to the PROPOSED TRANSFEREE; provided that the
DESIGNATED PURCHASER shall have no right to acquire the OFFERED SECURITIES unless the DESIGNATED PURCHASER acquires all of the
OFFERED SECURITIES. If such proposed TRANSFER involves consideration other than cash, any Person having rights under this subparagraph
(v) shall have the right to elect to pay, in lieu of such non-cash consideration, cash in an amount equal to the fair market value
of such non-cash consideration. Such offer shall be made by a written notice (the “NOTICE of PROPOSED TRANSFER”) delivered
to the COMPANY not less than thirty (30) days prior to the PROPOSED TRANSFER. Such NOTICE of PROPOSED TRANSFER shall set forth
the identity of the PROPOSED TRANSFEREE, the OFFERED SECURITIES proposed to be sold, the terms and conditions of the proposed sale,
including price per share and any other material terms and conditions or material facts relating to the proposed sale. In addition,
the HOSPITAL shall provide to the DESIGNATED PURCHASER all such other information relating to the OFFERED SECURITIES, the PROPOSED
TRANSFEREE and the proposed sale as the DESIGNATED PURCHASER may reasonably request. If the DESIGNATED PURCHASER does not accept
the HOSPITAL’s offer with respect to all of the OFFERED SECURITIES within fifteen (15) days after receipt of the NOTICE of
PROPOSED TRANSFER from HOSPITAL, the HOSPITAL shall have the right for a period of sixty (60) days following the sixtieth day after
the COMPANY received the NOTICE of PROPOSED TRANSFER from the HOSPITAL, to sell all of the OFFERED SECURITIES, but at not less
than the price, and upon terms not more favorable to the PROPOSED TRANSFEREE, than were contained in the NOTICE OF PROPOSED TRANSFER.
If the OFFERED SECURITIES are not sold within such 60-day period, such OFFERED SECURITIES shall continue to be subject to the requirements
of this subparagraph (v).

 

    	Page 4 of 5

    	 

    

  

(vi)         Miscellaneous.
The Shares, and all other shares of Common Stock and other securities of the COMPANY that may be issued to the Shareholders pursuant
to this Section 4.1(k), shall be duly authorized, validly issued, fully paid and nonassessable.

 

2.          Section
14.1 of the LICENSE AGREEMENT shall be amended to provide the following notices information for M.I.T., for all matters relating
to the LICENSE AGREEMENT, including equity and any equity actions after the initial issuance of shares:

 

	
        If to M.I.T.:
	Massachusetts Institute of Technology
	 	Technology Licensing Office, Room NE18-501
	 	One Cambridge Center, Kendall Square
	 	Cambridge, MA 02142-1601
	 	Attention: Director
	 	Tel: 617-253-6966
	 	Fax: 617-258-6790

 

3.          Except
as specifically modified or amended hereby, all other terms and conditions of the LICENSE AGREEMENT shall remain unchanged and
in full force and effect. Capitalized terms used herein and not defined shall have the meanings set forth in the LICENSE AGREEMENT.

 

IN WITNESS WHEREOF, the parties have caused
this First Amendment to be executed under seal by their duly authorized representatives.

 

The Effective Date of this First Amendment is March 8, 2013

 

	
        MASSACHUSETTS INSTITUTE OF TECHNOLOGY
	ENUMERAL BIOMEDICAL CORP.
	 	 
	By: /s/ Lita L. Nelsen	By: /s/ Arthur H. Tinkelenberg
	 	 
	Name: Lita L. Nelsen	Name: Arthur H. Tinkelenberg
	 	 
	Title: Director Technology Licensing Office	Title: President & CEO

 

    	Page 5 of 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]